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ABSTRACT 
 
 
 
Atherosclerosis, a chronic vascular disease, leads to the formation of atherosclerotic 
plaques in the arteries. The key events in atherogenesis include lipoprotein oxidation, foam 
cell formation, induced expression of cell adhesion molecules, invasion of inflammatory 
cells, smooth muscle cell proliferation, accumulation of the extracellular matrix and 
calcification. Angiogenesis is a physiological event involved in many pathological conditions 
such as the development of atherosclerosis and neovascular ocular diseases, and tumor 
progression. Members of the vascular endothelial growth factor (VEGF) family are crucial 
molecules in the process of angiogenesis. 
15-Lipoxygenase-1 (15-LO-1) is a lipid oxidizing enzyme the expression of which is 
induced in atherosclerotic lesions, but not in the normal vessel wall. 15-LO-1 has been 
suspected to play a role in tumor development, but the results are controversial. The aim of 
this thesis was to study the effects of 15-LO-1 in atherosclerosis, angiogenesis and 
tumorigenesis by virus mediated gene transfer techniques. 
Retroviral transduction of 15-LO-1 in vitro led to induced expression of cellular adhesion 
molecules and the binding of inflammatory cells to the transduced cells. Intramuscular and 
intravitreal adenoviral gene transfers of VEGF family members significantly increased the 
size and number of the capillaries, and capillary perfusion and permeability were 
significantly increased in the rabbit skeletal muscles. 15-LO-1 blocked these angiogenic 
effects by preventing the expression of the growth factors, by down-regulating VEGF 
receptor 2 and by reducing the bioavailability of nitric oxide. Tail vein adenoviral 15-LO-1 
gene transfers into mice resulted in increased 15-LO-1 expression mainly in liver, followed 
by induced lipid peroxidation and elevated caspase-3 activity. In a rat malignant glioma 
model, 15-LO-1 significantly prolonged the survival of the animals. 
In conclusion, 15-LO-1 may be involved in the early phases of atherosclerosis by 
inducing adhesion molecule expression and the binding of inflammatory cells to the 
endothelium. These studies suggest that 15-LO-1 could have potential in the treatment of 
pathologic angiogenic conditions, for example in neovascular ocular diseases. In addition, 
the prolongation of survival by 15-LO-1 detected in rat malignant glioma model indicates 
that further studies should be conducted to evaluate the potential of 15-LO-1 in the 
treatment of malignant glioma. 
 
National Library of Medicine Classification: QU 140, QU 475, QZ 52, QZ 266, WG 500, WG 
550 
Medical Subject Headings: Lipoxygenase; Atherosclerosis; Neovascularization, Pathologic; 
Neoplasms; Glioma; Gene Transfer Techniques; Transduction, Genetic; Retroviridae; 
Adenoviridae; NF-Kappa B; Vascular Endothelial Growth Factors; Cell Adhesion Molecules; 
Gene Expression; Inflammation; Endothelium; Capillaries; Capillary Permeability; Down-
Regulation; Nitric Oxide; Growth Substances; Placenta; Lipid Peroxidation; Caspase 3; 
Apoptosis; Disease Models, Animal; Rats 
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15 
INTRODUCTION 
 
Cardiovascular diseases are the 
leading cause of death worldwide, while 
cancers hold the third position after 
infections and parasitic diseases (World 
Health Organization, 2004). 
Atherosclerosis is the principal cause of 
many of the clinical cardiovascular 
complications such as coronary heart 
disease and peripheral artery disease. 
The main risk factors of atherosclerosis 
include high low density lipoprotein (LDL) 
cholesterol, high blood pressure, age, 
smoking, diabetes and male gender. 
Angiogenesis, where new capillaries 
are formed from pre-existing vessels, is a 
physiological process occurring for 
example during wound healing and the 
female reproductive cycle (Risau, 1997). 
Pathological angiogenesis occurs for 
instance in tumor growth and metastasis 
and neovascular ocular diseases. 
Members of the vascular endothelial 
growth factor (VEGF) family are 
important angiogenic molecules in health 
and disease (Ferrara et al., 2003). 
15-Lipoxygenase-1 (15-LO-1) is an 
enzyme capable of oxidizing fatty acids 
and LDL cholesterol. It is expressed in 
the macrophages present in the 
atherosclerotic lesion, but not in the 
normal vessel wall, and its reaction 
products have been detected in 
atherosclerotic lesions. Both pro- and 
anti-atherogenic activities for 15-LO-1 
have been presented (Cathcart et al., 
2000). 
15-LO-1 may also be involved in 
tumor growth (Fürstenberger et al., 
2006). However, rather conflicting results 
have been reported about the role of 15-
LO-1 in tumors, showing evidence of 
both anti- and pro-tumorigenic properties. 
Anti-tumorigenic effects of 15-LO-1 have 
been presented in mouse colorectal 
carcinoma xenograft models (Shureiqi et 
al., 2003; Nixon et al., 2004; Wu et al., 
2008), as well as in two different tumor 
models in transgenic mice over-
expressing human 15-LO-1 (Harats et al., 
2005). In this latter study, 15-LO-1 also 
resulted in aberrant angiogenesis in lung 
metastases. However, in prostate cancer, 
15-LO-1 displays quite an opposite effect, 
indicating that it plays a pro-tumorigenic 
role in this tissue (Nie et al., 2001). 
This thesis project was carried out to 
study the role of 15-LO-1 in 
atherogenesis, angiogenesis and 
tumorigenesis. Both retro- and 
adenovirus mediated gene transfer 
techniques were used in vitro in cell 
culture models, and recombinant 
adenoviruses were applied in animal 
experiments in vivo by various gene 
transfer routes.
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LITERATURE 
 
PATHOGENESIS OF 
ATHEROSCLEROSIS 
 
Atherosclerosis is a disease causing 
high morbidity and mortality in the 
industrial countries. It takes decades to 
develop clinically significant, advanced 
lesions, but the earliest signs can be 
detected already in the second decade of 
life. Atherosclerosis is a chronic, 
progressive disease initiated by lipid 
retention, oxidation and modification at 
susceptible sites of the vascular wall in 
major conduit arteries. The lesions 
predominantly develop into locations of 
adaptive intimal thickening (Insull, 2009). 
Atherosclerotic lesions can be classified 
into six classes, as depicted in Table I 
and Figure 1 (Stary et al., 1994; Stary et 
al., 1995).
 
 
Table I. Classification and characteristics of atherosclerotic lesions (Stary et al., 1994; 
Stary et al., 1995). 
 
Lesion type and description Characteristics 
I 
Macrophage foam cells 
Increase in macrophages and lipid 
accumulation into macrophages, foam cell 
formation 
II 
Fatty streaks 
All type I changes 
Smooth muscle cell -derived foam cells 
Extracellular lipid 
III 
Preatheroma, intermediate or transitional 
lesion 
All type II changes 
Increased extracellular lipid as separate 
pools 
IV 
Atheroma, fibrous plaque 
All type III changes, except the extracellular 
lipid as a coalesced lipid core 
V 
Fibroatheroma 
All type IV changes 
Collagenous fibrous cap 
Microscopical hemorrhages 
VI 
Complicated lesion 
All type V changes 
Fissure, hematoma, plaque rupture, 
thrombus 
17 
 
 
Figure 1. Lesion types of atherosclerosis. 
Modified from Stary et al., 1995. 
 
 
Foam cell and fatty streak 
formation 
 
The sites of diffuse intimal thickening, 
where atherosclerotic lesions 
predominantly develop, contain 
extracellular matrix (ECM) proteins such 
as biglycan and decorin in their outer 
layer. The initial extracellular lipid 
deposits colocalize with these 
proteoglycans (Nakashima et al., 2007). 
The neointimal thickening can be 
reduced by decorin, a small 
chondroitin/dermatan sulphate 
proteoglycan, which can reduce the ECM 
volume by inducing type I collagen 
synthesis and contraction (Järveläinen et 
al., 2004).  
The activation of endothelial cells 
(EC) induces the expression of several 
specific adhesion molecules, which 
together with inflammatory chemokines, 
produced by smooth muscle cells (SMC), 
mediate the adhesion of monocytes to 
the EC and their migration into the sub-
endothelial space. The invading 
monocytes are transformed into intimal 
macrophages, which uptake modified low 
density lipoprotein (LDL) and become 
foam cells filled with lipid. These early 
lipid changes and the first grossly visible 
lesions, the fatty streaks, can be 
reversed and are not yet considered as 
established atherosclerosis (Insull, 2009). 
 
 
Intermediate lesions and 
atheroma 
 
Intermediate lesions are characterized 
by the accumulation of lipid-rich necrotic 
debris and SMCs. Plaques contain a 
central lipid core, which is mainly devoid 
of cells. In fibroatheroma, which is 
considered the hallmark of established 
atherosclerosis, the lipid core is 
separated from the arterial lumen by a 
fibrous cap consisting of ECM and SMCs 
(Insull, 2009). 
More advanced lesions can be 
calcified and ulcerated at the luminal 
surface especially from the shoulder 
regions of the lesions. New fragile 
vessels growing into the lesion from the 
medial side can be vulnerable to produce 
haemorrhages within the blood vessel 
wall (Insull, 2009). 
 
 
Advanced lesions, plaque 
rupture and thrombus 
formation 
 
Advanced, complicated lesions can 
grow large enough to prevent blood flow 
causing, for example, stable ischaemic 
myocardial disease. The most important 
clinical complication is an acute rupture 
of the plaque, leading to thrombus 
formation occluding the vessel. This can 
evoke myocardial infarction or stroke 
(Insull, 2009). 
Type II lesion 
Type IV lesion 
(atheroma) 
Type VI lesion 
(complicated lesion) 
Type V lesion 
(fibroatheroma) 
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Intima 
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thickening 
(smooth 
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Small pools of 
extracellular 
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ANGIOGENESIS 
 
Angiogenesis is defined as the 
formation of new capillaries from pre-
existing vessels (Risau, 1997). 
Physiological angiogenesis is an 
essential phenomenon in development, 
tissue regeneration and reproduction. 
Pathologic angiogenesis is involved in 
many diseases such as tumor 
angiogenesis, rheumatoid arthritis and 
neovascular ocular diseases, of which 
the most important are retinopathy of 
prematurity, proliferative diabetic 
retinopathy and the vascular form of age 
related macular degeneration (Ferrara, 
2004). 
 
 
TUMORIGENESIS 
 
The development of tumors arises 
from abnormal function of genes. Tumor 
cells become self-sufficient in growth 
promoting signals and insensitive to 
growth inhibiting signals. They evade the 
normal pathway of programmed cell 
death and acquire unlimited potential for 
cell division. Angiogenesis is increased in 
order to supply the growing tumor tissue 
with oxygen and nutrients. Malignant cells 
also lose their interaction with ECM and 
can invade the surrounding tissue by 
degrading the basal membrane with 
proteolytic enzymes. Finally, cancer cells 
can metastasize to distant locations via 
blood and lymph vessels (Hanahan et al., 
2000). 
 
 
VASCULAR ENDOTHELIAL 
GROWTH FACTORS AND 
THEIR RECEPTORS 
 
Members of the VEGF family are key 
molecules in regulating both physiological 
and pathological angiogenesis and 
lymphangiogenesis (Figure 2) (Ferrara et 
al., 2003). In addition, VEGF signalling is 
required for the assembly of embryonic 
blood vessels in vasculogenesis, but is 
not required for the maintenance of these 
vessels (Argraves et al., 2002). 
The mammalian VEGF family 
comprises five secreted glycoproteins, 
which share a common structure of eight 
characteristically spaced cysteine 
residues. In addition, VEGFs have been 
isolated also from viruses (VEGF-E) and 
snake venoms (VEGF-F). VEGF family 
members mediate their biologic effects 
by binding to their cognate receptors 
VEGF receptor (VEGFR)-1, VEGFR-2 
and VEGFR-3. VEGF receptors are 
transmembrane receptor tyrosine 
kinases, which activate downstream 
signalling cascades upon ligand binding 
to their extracellular domain resulting in 
receptor dimerization and 
autophosphorylation of the intracellular 
receptor tyrosine kinases (Olsson et al., 
2006). 
Neuropilins (NRP) 1 and 2 are 
semaphorin receptors, but they can also 
bind some members of the VEGF family 
and act as co-receptors in angiogenic 
signalling (Soker et al., 1998; Gluzman-
Poltorak et al., 2000). In addition, 
heparan sulphate proteoglycans affect 
the bioactivity of VEGFs (Stringer, 2006)..
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Figure 2. VEGFs and their receptors in angiogenic and lymphangiogenic signalling. 
sVEGFR-1, soluble VEGFR-1; sNRP-1, soluble NRP-1; VEGF-E, viral VEGFs; VEGF-F, snake 
venom VEGFs; VEGF-C∆N∆C, the mature short form of VEGF-C; VEGF-D∆N∆C, the mature short 
form of VEGF-D. 
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Vascular endothelial growth 
factor (VEGF) family 
 
VEGF-A 
 
Vascular endothelial growth factor 
(VEGF or VEGF-A) was first identified as 
a vascular permeability factor secreted by 
tumor cells (Senger et al., 1983). VEGF-
A was originally purified and cloned as a 
secreted EC mitogen (Leung et al., 
1989). The human VEGF-A gene is 
composed of eight exons and is 
differentially spliced to yield at least 
seven mature isoforms: VEGF121, 
VEGF165 and VEGF189 (Tischer et al., 
1991), VEGF145 (Poltorak et al., 1997), 
VEGF162 (Lange et al., 2003), VEGF183 
(Lei et al., 1998), and VEGF206 (Houck et 
al., 1991). The numeric designation of 
the isoforms denotes the number of 
amino acids in each molecule. The 
different isoforms have distinct binding 
properties to heparan sulphate 
proteoglycan (Houck et al., 1992). The 
predominant isoform VEGF165 seems to 
have optimal bioavailability and biological 
potency due to its high mitogenic activity 
(Keyt et al., 1996) and intermediate 
binding affinity to heparan sulphate 
proteoglycan (Houck et al., 1992). 
VEGF-A is a ligand for VEGFR-1 (de 
Vries et al., 1992) and VEGFR-2 
(Terman et al., 1992; Quinn et al., 1993), 
which are widely expressed on vascular 
ECs (Kaipainen et al., 1993; Quinn et al., 
1993). VEGF-A165 (Soker et al., 1998; 
Mamluk et al., 2002) and VEGF-A121 
(Pan et al., 2007) also have affinity for 
the neuropilin receptor NRP-1, and 
VEGF-A145 and VEGF-A165 bind to NRP-2 
(Gluzman-Poltorak et al., 2000) (Figure 
2). 
VEGF-A transcription is induced in 
hypoxia (Shweiki et al., 1992) and in 
ischemia (Banai et al., 1994) by hypoxia-
inducible factor 1 (HIF-1) (Forsythe et al., 
1996). HIF-1 also stabilizes the VEGF-A 
messenger ribonucleic acid (mRNA) (Liu 
et al., 2002) as does also the ribonucleic 
acid (RNA) -binding protein HuR, which 
binds to the 3’ untranslated region (UTR) 
of VEGF-A (Levy et al., 1998). VEGF-A is 
expressed in multiple organs during 
development; in adults its expression is 
highest in lung and liver (Kaipainen et al., 
1993; Lagercrantz et al., 1998; Maharaj 
et al., 2006). 
VEGF-A induces EC survival, 
proliferation, migration, sprouting and 
tube formation (Ferrara, 2004). It also 
induces vasodilatation of arteries (Ku et 
al., 1993) via induction of the endothelial 
nitric oxide synthase (eNOS) (Hood et al., 
1998). The crucial role of VEGF-A in 
normal growth and survival as well as 
vascular development has been proven 
by VEGF inhibition (Gerber et al., 1999) 
and by knockout mice, where lack of 
even one copy of VEGF-A causes 
embryonic lethality (Carmeliet et al., 
1996; Ferrara et al., 1996). 
Transgenic mice overexpressing 
VEGF-A in the epidermis under keratin 
14 promoter exhibit abundant cutaneous 
angiogenesis and a skin condition 
resembling psoriasis (Xia et al., 2003). 
Over-expression of VEGF-A in skin under 
keratin K6 regulatory sequences induces 
angiogenesis, vascular permeability and 
accelerated tumor development (Larcher 
et al., 1998). VEGF-A is expressed 
practically in all solid human tumors 
studied so far (Ferrara, 2004). 
Results from phase III clinical trial 
revealed that bevacizumab (Avastin™), a 
monoclonal antibody against VEGF-A, 
significantly increased the survival of 
patients with metastatic colorectal cancer 
when used in combination with 
chemotherapy (Hurwitz et al., 2004). 
Bevacizumab and several other drugs 
targeted against VEGF (VEGF Trap, a 
decoy VEGF receptor; pegaptanib, an 
aptamer binding to VEGF-A165; 
ranibizumab, a monoclonal antibody 
fragment against VEGF-A) are currently 
being tested in phase III clinical trials for 
the treatment of different cancers and 
neovascular ocular diseases (U. S. 
National Institutes of Health, 
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http://www.clinicaltrials.gov, accessed 
October 2009). 
Gene transfer studies have shown 
that VEGF-A can induce angiogenic 
effects in ischemic (Wright, 2002) and 
normoxic (Rissanen et al., 2003b) rabbit 
hind limbs, in rabbit eyes after intravitreal 
gene transfer (Kinnunen et al., 2006), 
and in normoxic mouse hind limb 
muscles (Kholová et al., 2007). 
 
 
VEGF-B 
 
VEGF-B was cloned from human 
(Grimmond et al., 1996) and murine 
(Townson et al., 1996) brain 
complementary deoxyribonucleic acid 
(cDNA) libraries. The promoter region of 
VEGF-B contains binding sites for the 
early growth response 1 transcription 
factor, but on the contrary to VEGF-A, no 
HIF-1 binding sites (Silins et al., 1997). 
Consequently, VEGF-B expression is not 
regulated by hypoxia (Enholm et al., 
1997; Ristimäki et al., 1998). Two splice 
variants, VEGF-B167 and VEGF-B186, are 
expressed in human and mouse 
(Olofsson et al., 1996b) as a result of 
alternative splicing of exon 6 (Grimmond 
et al., 1996; Olofsson et al., 1996b; 
Townson et al., 1996). Both isoforms 
have an identical N-terminal region, but 
differ in their C-terminal regions. VEGF-
B167 has a C-terminal basic domain, 
which anchors it to the ECM (Olofsson et 
al., 1996a), whereas VEGF-B186 has a 
hydrophobic tail and is secreted 
(Olofsson et al., 1996b). VEGF-B binds 
to VEGFR-1 (Olofsson et al., 1998) and 
NRP-1 (Makinen et al., 1999) (Figure 2). 
It forms disulfide-linked homodimers as 
well as heterodimers with VEGF-A 
(Olofsson et al., 1996a; Olofsson et al., 
1996b). 
Expression of VEGF-B starts early in 
fetal development and is predominant in 
heart, central nervous system and brown 
fat tissue (Lagercrantz et al., 1996; 
Lagercrantz et al., 1998; Aase et al., 
1999). In the central nervous system, 
VEGF-B appears to be the only VEGF 
family member expressed at detectable 
levels (Lagercrantz et al., 1998). In 
adults, VEGF-B is mainly expressed in 
heart, brain, skeletal muscle, kidney and 
pancreas (Olofsson et al., 1996a; 
Olofsson et al., 1996b; Townson et al., 
1996; Lagercrantz et al., 1998). 
The exact role of VEGF-B in vivo is 
not yet clear. VEGF-B knockout mice are 
healthy and fertile, but they have smaller 
hearts and impaired recovery from 
experimentally induced myocardial 
ischemia (Bellomo et al., 2000).  
Administration of VEGF-B protein or 
VEGF-B gene transfer to ischemic hind 
limb skeletal muscle (Wright, 2002; 
Silvestre et al., 2003; Wafai et al., 2009) 
or myocardium (Li et al., 2008; 
Lähteenvuo et al., 2009) results in 
increased vascularization, whereas 
VEGF-B does not show angiogenic 
effects in periadventitial tissue (Bhardwaj 
et al., 2003) or in normoxic hind limb 
skeletal muscle (Rissanen et al., 2003b). 
Transgenic overexpression of VEGF-B in 
ECs induces vessel growth without 
changes in vascular permeability (Mould 
et al., 2005). In transgenic mice 
expressing VEGF-B only in cardiac 
myocytes, no increases in vessel 
numbers are detected, but VEGF-B 
induces concentric myocardial 
hypertrophy and alters lipid metabolism 
resulting in mitochondrial damage and 
elevated mortality (Karpanen et al., 
2008). 
 
 
VEGF-C 
 
VEGF-C was originally cloned from 
human PC-3 prostate carcinoma cells 
(Joukov et al., 1996). VEGF-C 
expression is not regulated by hypoxia, 
but is induced by proinflammatory 
cytokines (Enholm et al., 1997; Ristimäki 
et al., 1998). It is synthesized as a 
precursor protein, but is proteolytically 
processed (Joukov et al., 1996) from the 
N- and C-terminal ends, first 
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intracellularly by proprotein convertases 
(Siegfried et al., 2003) and further 
extracellularly by plasmin (McColl et al., 
2003) to produce a fully active mature 
form. The precursor protein binds only to 
VEGR-3. The proteolytic processing not 
only increases this affinity but also 
introduces a new binding affinity, since 
the fully processed protein can also bind 
VEGFR-2 (Kukk et al., 1996; Lee et al., 
1996; Joukov et al., 1997) (Figure 2). 
VEGF-C also interacts with NRP-1 and 
NRP-2 (Kärpänen et al., 2006). 
VEGF-C is expressed during 
embryonic development especially in the 
regions, where the lymphatic vasculature 
has developed (Kukk et al., 1996), 
whereas in adults, VEGF-C expression is 
detected in multiple tissues (Kukk et al., 
1996; Partanen et al., 2000). VEGF-C 
induces mitogenesis, migration and 
survival of ECs and increases vascular 
permeability (Lee et al., 1996; Joukov et 
al., 1997; Zhao et al., 2007). VEGF-C is 
indispensable in embryonic 
lymphangiogenesis, since embryos 
lacking VEGF-C are not viable and fail to 
form the initial lymph sacs required for 
the generation of lymphatic vasculature 
(Karkkainen et al., 2004). Transgenic 
mice overexpressing VEGF-C either 
inducibly or constitutively in the epidermis 
or hair follicles have induced lymphatic 
vessel hyperplasia in the skin (Jeltsch et 
al., 1997; Veikkola et al., 2001; Lohela et 
al., 2008). Inducible overexpression of 
VEGF-C in the vascular endothelium 
leads to lymphangiogenesis postnatally 
and in adult tissues, wheras in embryos 
can a strong induction in angiogenesis 
also be detected (Lohela et al., 2008). 
In experimental models, VEGF-C 
promotes tumor lymphangiogenesis, 
metastasis and growth (Karpanen et al., 
2001; Mandriota et al., 2001). VEGF-C 
has shown potential in inducing 
therapeutic lymphangiogenesis in 
pathological conditions of lymphatic 
insufficiency (Karkkainen et al., 2001; 
Szuba et al., 2002; Tammela et al., 2007; 
Liu et al., 2008). It also induces 
therapeutic angiogenesis and 
lymphangiogenesis in diabetic wound 
healing (Saaristo et al., 2006). 
Gene transfer studies with VEGF-C 
have revealed that it induces 
angiogenesis in ischemic settings 
(Witzenbichler et al., 1998; Pätilä et al., 
2006). Ectopic expression of recombinant 
VEGF-C induces angiogenesis in the 
mouse cornea and the chicken embryo 
(Cao et al., 1998). In skin, VEGF-C 
induces lymphangiogenesis (Enholm et 
al., 2001) and changes in blood vessel 
morphology, but no sprouting 
angiogenesis (Saaristo et al., 2002). 
Prevention of VEGF-C expression was 
reported to inhibit lymphangiogenesis 
and tumor growth (He et al., 2008). A 
correlation between VEGF-C expression 
and lymph node metastases has been 
detected in a number of different tumors 
(Alitalo et al., 2002). 
 
 
VEGF-D 
 
VEGF-D (also called c-fos -induced 
growth factor) was originally cloned from 
mouse fibroblasts (Orlandini et al., 1996) 
and mouse and human lung cDNA 
libraries (Yamada et al., 1997; Achen et 
al., 1998). VEGF-D is a secreted dimeric 
protein (Orlandini et al., 1996). It is a 
ligand and activator of both VEGR-2 and 
VEGFR-3, but does not bind to VEGFR-1 
(Achen et al., 1998). VEGF-D also 
interacts with NRP-1 and NRP-2 
(Kärpänen et al., 2006). 
VEGF-D is structurally most closely 
related to VEGF-C (Yamada et al., 1997) 
and undergoes similar proteolytic 
processing of the N- and C-terminal ends 
by plasmin and proprotein convertases 
i.e. like VEGF-C (McColl et al., 2003; 
McColl et al., 2007). The proteolytic 
processing regulates the biological 
activity and receptor specificity of VEGF-
D. The unprocessed, long form of VEGF-
D binds predominantly to VEGFR-3. 
Proteolytic processing of the N- and C-
terminal ends results in the short, mature 
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form of the protein (VEGF-D∆N∆C) 
containing only the VEGF homology 
region, which increases the binding 
affinity by 290-fold to VEGFR-2 and by 
40-fold to VEGFR-3 (Stacker et al., 1999; 
McColl et al., 2003) (Figure 2). Mouse 
VEGF-D only binds VEGR-3 (Baldwin et 
al., 2001a). VEGF-D is expressed in 
many tissues in adults (Yamada et al., 
1997; Achen et al., 1998; Partanen et al., 
2000; Baldwin et al., 2001b) and during 
embryonic development (Avantaggiato et 
al., 1998; Partanen et al., 2000), the 
expression being most prominent in 
lungs (Yamada et al., 1997; Farnebo et 
al., 1999; Stacker et al., 1999). 
VEGF-D has been proposed to have a 
role in tumor angiogenesis (Marconcini et 
al., 1999) and lymphangiogenesis (Achen 
et al., 2002). However, it does not seem 
to play a crucial role in embryonic 
lymphangiogenesis, since VEGF-D 
deficient mice do not display any 
profound defects in their lymphatic 
vessels (Baldwin et al., 2005). 
Transgenic VEGF-D mice produced by 
lentiviral transgenesis have the highest 
expression levels of the mature form of 
human VEGF-D in skeletal muscle, skin, 
pancreas and heart. These animals have 
increased capillary densities in their 
skeletal and cardiac muscles and 
enhanced muscle regeneration after 
ischemia, but they also have increased 
susceptibility to tumor formation 
(Kärkkäinen et al., 2009). Adenoviral 
gene transfer studies in various animal 
models show that VEGF-D is a potent 
stimulator of both angiogenesis and 
lymphangiogenesis. VEGF-D∆N∆C 
induces angiogenesis in rat cremaster 
muscle and in a mouse skin model 
(Byzova et al., 2002), in rabbit and mouse 
hind limb skeletal muscle (Rissanen et 
al., 2003b; Kholová et al., 2007) and in 
pig myocardium (Rutanen et al., 2004). 
Both VEGF-D and VEGF-D∆N∆C can 
induce angiogenesis in rabbit carotid 
arteries after periadventitial gene transfer 
(Bhardwaj et al., 2003; Bhardwaj et al., 
2005). Lymphangiogenesis is induced by 
VEGF-D∆N∆C in mouse skin (Byzova et 
al., 2002) and in lymph node-excised 
mice (Tammela et al., 2007), and by 
VEGF-D in rabbit hind limb skeletal 
muscle (Rissanen et al., 2003b). 
 
 
Placental growth factor 
 
Placental growth factor (PlGF) was 
originally isolated from human placenta 
cDNA library (Maglione et al., 1991). It is 
also expressed in human vascular ECs 
(Barleon et al., 1994) and has been 
detected in fetal liver, heart, lung and 
kidney (Kaipainen et al., 1993). Four 
secreted PlGF isoforms have been 
described: PlGF-1 (Maglione et al., 1991; 
Park et al., 1994), PlGF-2 (Hauser et al., 
1993; Maglione et al., 1993; Park et al., 
1994), PlGF-3 (Cao et al., 1997) and 
PlGF-4 (Yang et al., 2003). PlGFs form 
homodimers (Maglione et al., 1991; Park 
et al., 1994; Cao et al., 1997), but also 
natural heterodimers with VEGF-A have 
been detected, with reduced EC 
mitogenic potential as compared with the 
VEGF homodimers (DiSalvo et al., 1995; 
Cao et al., 1996). 
PlGFs mediate their effects via 
VEGFR-1 and do not bind to VEGFR-2 
(Park et al., 1994; Terman et al., 1994; 
Sawano et al., 1996). PlGF-2 binds also 
to NRP-1 (Migdal et al., 1998; Mamluk et 
al., 2002), and the PlGF/VEGF 
heterodimers to VEGFR-2 (Cao et al., 
1996) (Figure 2). 
PlGF induces EC proliferation 
(Maglione et al., 1991; Ziche et al., 
1997a), migration (Ziche et al., 1997a; 
Migdal et al., 1998) and angiogenesis 
(Ziche et al., 1997a; Luttun et al., 2002b; 
Roy et al., 2005). PlGF modulates inter- 
and intramolecular crosstalk between 
VEGR-1 and VEGFR-2 by activating 
VEGFR-1, which evokes the 
transphosphorylation of VEGFR-2 
(Autiero et al., 2003), and it has also 
been shown to induce VEGF-A 
expression (Roy et al., 2005). However, it 
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has also been postulated that the 
PlGF/VEGF heterodimers have an 
antagonistic effect on VEGF -mediated 
angiogenic signalling (Eriksson et al., 
2002; Xu et al., 2006; Schomber et al., 
2007). 
Overexpression of PlGF in the skin of 
transgenic mice leads to increased 
vascularization (Odorisio et al., 2002; 
Marcellini et al., 2006), enhanced vessel 
permeability, and expression of VEGFR-1 
and VEGFR-2 (Odorisio et al., 2002), as 
well as increased melanoma growth and 
metastasis spreading (Marcellini et al., 
2006). Mice deficient in PlGF suffer 
impaired angiogenesis, vascular 
permeability and arteriogenesis in 
pathological conditions (Carmeliet et al., 
2001; Luttun et al., 2002a). PlGF has 
also been implicated in the induction of 
cutaneous inflammation in inflammatory 
angiogenesis (Oura et al., 2003). Gene 
transfer studies with PlGF show that it 
has potential in inducing therapeutic 
angiogenesis in ischaemic hind limbs, 
resulting in increased exercise tolerance 
(Korpisalo et al., 2008). 
A role for PlGF in tumor 
vasculogenesis and angiogenesis has 
been proposed, but the current results 
are controversial (Matsumoto et al., 
2003; Li et al., 2006a; Schomber et al., 
2007). PlGF may also play a role in 
arteriogenesis by activating monocytes 
(Pipp et al., 2003; Scholz et al., 2003), in 
epithelial differentiation (Zhang et al., 
2003), and in the development of 
atherosclerosis (Khurana et al., 2005; 
Pilarczyk et al., 2008), proliferative 
diabetic retinopathy (Khaliq et al., 1998), 
and choroidal neovascularization (Rakic 
et al., 2003). 
 
 
Receptors for vascular 
endothelial growth factors 
 
VEGF family members mediate their 
functions via a family of VEGFRs, which 
are high-affinity receptor protein-tyrosine 
kinases. They consist of an extracellular 
ligand-binding component containing 
seven immunoglobulin-like domains, a 
single transmembrane segment, an 
intracellular tyrosine kinase domain split 
by a kinase insert, and a downstream 
carboxy terminal domain (Olsson et al., 
2006) (Figure 2). 
 
 
VEGF receptor 1 
 
VEGFR-1 was isolated from normal 
human placenta RNA (Shibuya et al., 
1990). There is extensive expression of 
VEGFR-1 in human heart, lung, kidney, 
placenta and vascular ECs (Kaipainen et 
al., 1993; Barleon et al., 1994). The 
mouse homolog fms-like tyrosine kinase-
1 is expressed in vascular ECs both 
during embryonic vascular development 
(Peters et al., 1993; Breier et al., 1995; 
Fong et al., 1996) and in adult tissues 
(Peters et al., 1993). The expression of 
VEGFR-1 is induced by hypoxia (Detmar 
et al., 1997; Gerber et al., 1997) via an 
HIF-1 dependent mechanism (Gerber et 
al., 1997).  
VEGFR-1 binds VEGF-A (de Vries et 
al., 1992; Breier et al., 1995; Clauss et 
al., 1996), VEGF-B (Olofsson et al., 
1998) and PlGF (Park et al., 1994; 
Terman et al., 1994; Clauss et al., 1996; 
Sawano et al., 1996) with high affinities 
(Figure 2). However, VEGF-A binding to 
VEGFR-1 mediates only weak mitogenic 
signalling (Waltenberger et al., 1994). 
VEGFR-1 knockout mice have 
abnormal vascular channels and die 
during early embryogenesis (Fong et al., 
1995). Developmental studies have 
shown that VEGFR-1 plays a major role 
in vasculogenesis by establishing 
vascular endothelium (Fong et al., 1996), 
by controlling EC division and sprout 
formation (Kearney et al., 2002; Kearney 
et al., 2004; Kappas et al., 2008), and by 
modulating VEGFR-2 signalling (Roberts 
et al., 2004; Kappas et al., 2008). The 
tyrosine kinase domain of VEGFR-1 is 
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dispensable (Hiratsuka et al., 1998), 
whereas the ligand-binding domain and 
the transmembrane domain are essential 
for normal development (Hiratsuka et al., 
2005). VEGFR-1 signalling promotes 
both angiogenesis and 
lymphangiogenesis by increasing bone 
marrow-derived macrophage recruitment 
(Murakami et al., 2008). VEGFR-1 is also 
involved in monocyte/macrophage 
chemotaxis (Barleon et al., 1996; Clauss 
et al., 1996; Hiratsuka et al., 1998; 
Sawano et al., 2001; Tchaikovski et al., 
2008) and recruitment of endothelial (Li 
et al., 2006a) and myeloid (Luttun et al., 
2002b) progenitor cells.  
A soluble, truncated form of VEGFR-1 
(sVEGFR-1) is produced through 
alternative splicing (Kendall et al., 1993; 
He et al., 1999b). The sVEGFR-1 inhibits 
VEGF-A mediated signalling by 
functioning as a VEGF-A sink, thus 
binding and depleting free circulating 
VEGF-A (Kendall et al., 1993; Hornig et 
al., 2000; Inoue et al., 2000) as well as by 
heterodimerizing with VEGFR-2 (Kendall 
et al., 1996). Adenoviral gene transfer of 
soluble VEGFR-1 into rat femoral muscle 
inhibits the formation of subretinal 
neovascularization, a serious 
complication in age related macular 
degeneration (Honda et al., 2000). 
Adenovirus mediated gene transfer of 
soluble ligand-binding ectodomain of 
VEGFR-1 also prevents endogenous 
angiogenesis and inhibits perfusion in 
animals with experimental ischemia 
(Jacobi et al., 2004). 
 
 
VEGF receptor 2 
 
VEGFR-2 was originally cloned from 
human EC cDNA library and named 
kinase insert domain-containing receptor 
(Terman et al., 1991). It is expressed in 
multiple tissues during development 
(Kaipainen et al., 1993), in cultured 
vascular ECs and in placenta (Barleon et 
al., 1994). The murine homolog fetal liver 
kinase 1 isolated from hematopoietic 
tissue is also expressed in a wide variety 
of non-hematopoietic tissues (Matthews 
et al., 1991), where the expression is 
restricted to the vascular endothelium 
during development (Millauer et al., 1993; 
Quinn et al., 1993). Fetal liver kinase 1 is 
highly expressed in the developing brain, 
but its expression is drastically reduced in 
adults when proliferation has ceased 
(Millauer et al., 1993). VEGFR-2 
expression is not transcriptionally 
regulated by hypoxia (Gerber et al., 
1997), but hypoxia decreases VEGFR-2 
mRNA stability (Olszewska-Pazdrak et 
al., 2009). 
VEGFR-2 binds VEGF-A (Terman et 
al., 1992; Quinn et al., 1993), the mature 
forms of VEGF-C (Joukov et al., 1997) 
and VEGF-D (Achen et al., 1998), VEGF-
E (Ogawa et al., 1998) and VEGF-F 
(Yamazaki et al., 2003) (Figure 2). 
VEGFR-2 transcription is induced by 
ligand binding, indicative of a positive 
feedback mechanism for VEGF action 
(Shen et al., 1998). 
VEGFR-2 is the major signal 
transducer of both physiological and 
pathological angiogenesis. VEGFR-2 
deficiency (Shalaby et al., 1995) and 
especially a mutation in the tyrosine 
residue 1173 (Sakurai et al., 2005) are 
lethal early in embryogenesis since there 
is a lack of vasculogenesis. VEGFR-2 
mediates EC migration and vascular 
permeability (Gille et al., 2001), EC 
proliferation (Gille et al., 2001; Li et al., 
2002), tube formation (Koolwijk et al., 
2001; Yang et al., 2001) and hypotension 
(Li et al., 2002). VEGFR-2 activates 
several signal transduction pathways in 
ECs (Kroll and Waltenberger, 1997; Wu 
et al., 2000; Gille et al., 2001), VEGF-A 
induces nitric oxide synthase (NOS) 
expression via VEGFR-2 (Kroll and 
Waltenberger, 1998) and VEGFR2 
mediates nitric oxide (˙NO) release from 
ECs (Kroll and Waltenberger, 1999). The 
importance of NOS for the VEGF-A 
induced angiogenesis has been 
presented by using NOS inhibitors 
(Papapetropoulos et al., 1997; Ziche et 
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al., 1997b) and eNOS knockout mice 
(Fukumura et al., 2001). In addition to 
mediating angiogenic signalling, VEGFR-
2 may also be involved in lymphatic 
vessel enlargement, without affecting 
vessel sprouting (Wirzenius et al., 2007). 
Retrovirally mediated dominant-
negative inhibition of VEGFR-2 
suppresses the growth of many tumor 
types in an athymic mouse model, where 
cells producing truncated VEGFR-2 
lacking the kinase domain are implanted 
subcutaneously together with tumor cells 
(Millauer et al., 1994; Millauer et al., 
1996). Adenovirus mediated gene 
transfer of soluble ligand-binding 
ectodomain of VEGFR-2 prevents 
endogenous angiogenesis and inhibits 
perfusion in animals with experimental 
ischemia (Jacobi et al., 2004). VEGFR-2 
antibodies and tyrosine kinase inhibitors 
targeting either VEGFR-2 or multiple 
growth factor receptors are currently 
being tested for the treatment of different 
cancers in clinical trials (U. S. National 
Institutes of Health, 
http://www.clinicaltrials.gov, accessed 
October 2009). 
 
 
VEGF receptor 3 
 
VEGFR-3 (fms-like tyrosine kinase 4) 
was cloned from a human placenta cDNA 
library (Galland et al., 1992). VEGFR-3 is 
expressed in multiple tissues during 
development (Pajusola et al., 1992; 
Galland et al., 1993; Kaipainen et al., 
1993; Borg et al., 1995; Partanen et al., 
2000), especially in the ECs of 
developing vessels (Kaipainen et al., 
1993; Kukk et al., 1996). In adulthood, 
VEGFR-3 expression becomes restricted 
to lymphatic ECs, some high endothelial 
venules and fenestrated capillaries 
(Kaipainen et al., 1995; Partanen et al., 
2000), with the exception of tumor 
tissues, where it is expressed also in 
vascular ECs and is possibly involved in 
maintaining the integrity of the EC lining 
during angiogenesis (Kubo et al., 2000; 
Witmer et al., 2001; Petrova et al., 2008). 
VEGFR-3 is also expressed in blood 
vessel endothelium in chronic 
inflammatory wounds (Paavonen et al., 
2000). 
VEGFR-3 binds VEGF-C (Joukov et 
al., 1996; Joukov et al., 1997) and VEGF-
D (Achen et al., 1998), but not VEGF-A 
(Pajusola et al., 1994) (Figure 2). 
Proteolytic processing of VEGF-C and –D 
increases their affinity to VEGFR-3 
(Joukov et al., 1997; Stacker et al., 1999; 
McColl et al., 2003). VEGFR-3 
transduces signalling for lymphatic EC 
survival, growth and migration (Mäkinen 
et al., 2001b). 
Targeted inactivation of VEGFR-3 
shows that VEGFR-3 signalling is 
essential in the development of functional 
blood vessels during embryogenesis 
(Dumont et al., 1998). Recent studies 
with genetic targeting of VEGFR-3 and 
inhibition of VEGFR-3 signalling have 
revealed that VEGFR-3 is involved in 
angiogenic sprouting and regulation of 
the vascular network formation 
(Tammela et al., 2008). The cooperative 
properties of VEGFR-2 and VEGFR-3 
are required for lymphatic migration and 
proliferation, whereas either one of the 
receptors is sufficient to organize the 
lymphatic ECs into functional capillaries 
(Goldman et al., 2007). 
Studies with transgenic mice 
overexpressing VEGF-D or a VEGFR-3-
specific mutant of VEGF-C under the 
keratin 14 promoter in the hair follicles 
have shown that activation of the 
VEGFR-3 signalling pathway is sufficient 
to induce lymphangiogenesis in the skin 
(Veikkola et al., 2001). Transgenic mice 
expressing detectable levels of circulating 
extracellular ligand binding soluble form 
of VEGFR-3 under the keratin 14 
promoter in keratinocytes have reduced 
lymphangiogenesis, resulting in 
lymphedema (Mäkinen et al., 2001a). 
Inhibition of VEGFR-3 signalling in animal 
tumor models suppresses tumor 
lymphangiogenesis and lymph node 
metastasis (He et al., 2002; Shimizu et 
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al., 2004; Lin et al., 2005) as well as 
tumor angiogenesis and 
lymphangiogenesis with a consequent 
reduction in tumor growth in animal 
models (Laakkonen et al., 2007; 
Tammela et al., 2008). 
 
 
LIPOXYGENASES 
 
Classification 
 
Lipoxygenases (LO) are a family of 
nonheme iron dioxygenases capable of 
inserting molecular oxygen regio- and 
stereospecifically into the 1,4-pentadiene 
structures of polyunsaturated fatty acids, 
thus producing their corresponding 
hydroperoxy derivatives (Yamamoto, 
1992; Fürstenberger et al., 2006). The 
primary lipid peroxidation products from 
arachidonic acid (AA) and linoleic acid 
(LA) are hydro-peroxyeicosatetraenoic 
acid (HPETE) and 
hydroperoxyoctadecadienoic acid 
(HPODE), respectively (Fürstenberger et 
al., 2006). These are readily reduced to 
their respective hydroxy fatty acids, 
hydroxyeicosatetraenoic acid (HETE) and 
hydroxyoctadecadienoic acid (HODE). 
LOs have been isolated from plants, 
animals and micro-organisms (Kuhn et 
al., 2002). 
Mammalian LOs were first classified 
according to their positional specificity of 
oxygenating AA, resulting in 
nomenclature of 5-, 8-, 12- and 15-LOs 
(Kuhn and Thiele, 1999). However, this 
classification has proved to be over-
simplified, since the positional specificity 
of the enzymes is not absolute, but 
depends on the structure of the substrate 
and the species in question. Thus, 
another classification based on the 
phylogenetic relatedness has been 
proposed, grouping the enzymes into four 
different phylogenetic groups, namely 
12(S)/15(S)-LOs (the reticulocyte and 
leukocyte type LOs), platelet-type 12(S)-
LOs, 5(S)-LOs and epidermis-type LOs 
(Fürstenberger et al., 2002) (Figure 3). 
The phylogenetic group of the mouse 
epidermal 12(S)-LO has not yet been 
clearly identified (Fürstenberger et al., 
2007). 
 
 
Substrate specificity, products 
and physiological roles 
 
All LOs are intracellular enzymes 
involved in the regulated metabolism of 
AA (Figure 4), a common constituent of 
cell membrane phospholipids. In 
response to a diverse set of external 
stimuli, free AA is released from the 
membranes by the action of 
phospholipases. The released AA is 
consequently metabolized via the cyclo-
oxygenase or the LO pathways (Sigal, 
1991). In addition to AA, the LOs can 
also metabolize a number of other 
polyenoic fatty acids with various 
substrate specificities. 
5-LO reacts predominantly with C20 
fatty acids (Ochi et al., 1983). 5-LO 
initiates leukotriene synthesis from AA 
together with 5-LO activating protein 
(Dixon et al., 1990). The association of 
leukotrienes with asthma and allergic 
rhinitis have been established in clinical 
trials. 5-LO and leukotrienes have also 
been implicated as playing a role in other 
allergic diseases as well as in 
inflammatory diseases, pulmonary 
syndromes, cancer and atherosclerosis 
(Peters-Golden and Henderson, 2007). 
The mouse 8(S)-LO can use AA and 
LA as a substrate (Jisaka et al., 1997). 
There are three distinct isoforms of 
12(S)-LOs, which differ in their substrate 
specificities: the platelet-type 12(S)-LO 
reacts mainly with AA, whereas the 
leukocyte-type 12(S)-LO displays a wide 
substrate specificity, and can react with 
C18 and C22 fatty acids as rapidly as with 
AA (Yamamoto, 1992). The mouse 
epidermal 12(S)-LO (Aloxe) produces 
mainly 12(S)-HETE and minor amounts 
of 15(S)-HETE from AA (Funk et al., 
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1996). The physiological roles of the 
epidermal-type and platelet-type LOs are 
still largely unknown. Mouse 8-(S)-LO, its 
human ortholog 15(S)-LO-2, 12(R)-LO 
and e-LOX-3 have been suggested to be 
involved in the terminal differentiation of 
epidermal keratinocytes (Fürstenberger 
et al., 2002; Fürstenberger et al., 2007), 
and e-LOX-3 also in adipocyte 
differentiation (Fürstenberger et al., 
2007). 8-(S)-LO may also have a critical 
role in mouse skin tumor development 
(Fürstenberger et al., 2002). Platelet-type 
12(S)-LO has been suggested to be 
involved in skin tumor development 
(Krieg et al., 1995).
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Figure 3. Phylogenetic tree of mammalian LOs. Genetic distance for all pairs was calculated 
with the Geneious Pro 4.5.4 software. Sequence accession numbers are according to 
Fürstenberger et al., 2002. 
 
 
Reticulocyte 15-LO (15-LO-1) shows 
wide substrate specificity in terms of 
carbon chain length: it can oxygenate 
unsaturated C18, C20, and C22 fatty acids 
(Yamamoto, 1992). The optimal 
substrate for 15-LO-1 is LA (Kühn et al., 
1993a), producing mainly 13(S)-HPODE 
(Kühn et al., 1993b). The reaction with 
AA produces mostly 15(S)-HPETE, but 
also 12(S)-HPETE as a side product 
(Bryant et al., 1982; Kühn et al., 1993a; 
Kühn et al., 1993b). In contrast, the 15-
LO-2 isolated from human hair roots 
produces only 15(S)-HPETE from AA, 
and LA is a poor substrate (Brash et al., 
1997).
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Figure 4. Arachidonic acid metabolism by mammalian lipoxygenases. Modified from 
Viita and Ylä-Herttuala, 2000. 
 
 
15-LO-1 has been shown to be 
involved in the controlled degradation of 
reticulocyte mitochondria during red cell 
maturation (Schewe et al., 1975; 
Rapoport et al., 1979; Grüllich et al., 
2001). It preferentially acts on 
mitochondrial membranes compared with 
cell membranes (Rapoport et al., 1979) 
and this leads to inactivation of 
respiratory enzymes (Kroschwald et al., 
1989). The disruption of the 
mitochondrial membrane is mediated by 
induction of collapse of the mitochondrial 
pH gradient (Vijayvergiya et al., 2004) 
leading to the dissipation of mitochondrial 
membrane potential and release of 
cytochrome c (Maccarrone et al., 2001). 
15-LO-1 protein expression is 
temporally tightly regulated during red cell 
maturation: it is not expressed in bone 
marrow, but the expression begins in the 
transition phase from late erythroblast to 
early reticulocyte stages, peaks during 
reticulocyte maturation and then declines 
until no protein is expressed in the 
erythrocyte (Rapoport et al., 1979; Thiele 
et al., 1979; Thiele et al., 1982; Nadel et 
al., 1991). Production of characteristic 
15-LO-1 hydroxy fatty acids can be 
induced in experimental reticulocytosis 
(Kühn et al., 1990; Kühn and Brash, 
1990). 
A similar pattern of 15-LO-1 
expression is detected in the central fibre 
cell of the eye lens, where degradation of 
the nuclei and organelles results in the 
formation of a transparent cell filled with 
crystallins. 15-LO-1 is localized to the 
region where organelle degradation 
occurs and is absent from the outer 
layers, which contain precursor and 
immature fibre cells as well as mature 
central fibres (van Leyen et al., 1998). In 
rat liver, 15-LO-1 is involved in the 
disruption of peroxisomal membranes 
and programmed degradation of 
peroxisomes (Yokota et al., 2001). A 
more generalized function for 15-LO-1 
5-HPETE 
leukotrienes 
5-LO 12-LO 
12-HPETE 
12-HETE 
arachidonic acid 8-LO 15-LO 
8-HPETE 
8-HETE 
15-HPETE 
15-HETE 
8,15-diHETE 
lipoxins 
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has been proposed in the programmed 
degradation of various intracellular 
organelles by membrane integration, 
induction of pore formation and 
permeabilization of the organelle 
membranes (van Leyen et al., 1998; van 
Leyen, 1998; Vijayvergiya et al., 2004). 
There are two important differences 
between the reticulocyte 15-LO-1 and 
other mammalian LOs with respect to 
atherogenesis. The optimal substrate for 
reticulocyte 15-LO-1 is LA, which is 
abundant in LDL. 15-LO-2 is also capable 
of binding LA with a similar affinity, but 
the catalytic activity of 15-LO-1 is two to 
four fold higher (Kilty et al., 1999). In 
addition, 15-LO-1 is able to oxidize not 
only free polyenoic fatty acids, but also 
esterified fatty acids in more complex 
substrates such as phospholipids, 
cholesterol esters, lipoproteins and 
biomembranes, without the preceding 
action of phospholipases (Kuhn et al., 
2002). 
 
 
Reticulocyte 15-lipoxygenase 
(15-LO-1) 
 
Structure and substrate binding 
 
Reticulocyte 15-LO-1 consists of two 
domains, the C-terminal substrate 
binding domain containing a hydrophobic 
pocket and an N-terminal β-barrel 
domain (Gillmor et al., 1997). The 
enzymatic activity is localized to the C-
terminal catalytic domain, whereas both 
the N-terminal β-barrel domain and the 
C-terminal catalytic domain determine 
the membrane binding properties of the 
enzyme (Walther et al., 2002). 15-LOs 
contain one non-heme iron molecule in 
their postulated catalytic region. They 
exist usually in the inactive ferrous (Fe2+) 
state, but oxidation to the active ferric 
(Fe3+) form is needed for catalysis 
(Boyington et al., 1994). 
The product specificity of human 15-
LO-1 in vitro has been shown to depend 
on the substrate concentration (Schnurr 
et al., 1996; Belkner et al., 1998), 
incubation temperature (Murray et al., 
1988; Belkner et al., 1998; Heydeck et 
al., 2001) and incubation time (Lass et 
al., 1996; Schnurr et al., 1996; Belkner et 
al., 1998; Heydeck et al., 2001). 
 
 
Cloning and expression 
 
15-LO-1 was originally purifed from 
rabbit reticulocytes (Rapoport et al., 
1979). Cloning and sequencing of the 
rabbit and human reticulocyte 15-LO-1 
cDNAs showed that they encode 
predicted polypeptides of 661 amino 
acids and approximately 75 kilo Dalton 
(kDa) (Sigal et al., 1988; Fleming et al., 
1989). In addition to reticulocytes, 15-LO-
1 is highly expressed in human 
eosinophils, interleukin (IL) -4 and -13 
treated human monocytes and alveolar 
macrophages (Kühn, 1996). The protein 
is localized to the cytoplasm (Nadel et al., 
1991). Cloning of the murine leukocyte 
12-LO revealed that it is the functional 
homolog of the human reticulocyte 15-
LO-1. The murine 12/15-LO is expressed 
in peritoneal macrophages, lung, spleen, 
heart, liver, reticulocytes, pineal gland, 
pituitary gland and kidney (Chen et al., 
1994; Freire-Moar et al., 1995). 
 
 
Regulation of expression 
 
Human reticulocyte 15-LO-1 and its 
species homologs rabbit reticulocyte 15-
LO-1 and murine 12/15-LO are strictly 
regulated enzymes at the transcriptional, 
translational, and enzyme activity levels. 
 
 
Transcriptional regulation 
 
The reticulocyte 15-LO-1 gene 
promoter contains interleukin responsive 
elements (Kritzik et al., 1997; Kelavkar et 
al., 1998) and a GATA-binding protein 
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(GATA) binding region mediating 
repression of 15-LO-1 expression 
(O'Prey et al., 1995; Kamitani et al., 
2000). A transcriptional silencer only 
functioning in non-erythroid cells is 
located in the 5’ flanking region of the 
rabbit 15-LO-1 gene (O'Prey et al., 1995), 
and one exact match to the consensus 
sequence of this element is also found in 
the human 15-LO-1 gene (Kritzik et al., 
1997). 
Numerous studies have shown that 
IL-4 and -13 are able to induce 15-LO-1 
mRNA and protein expression and 
enzyme activity both in vitro in various 
cell lines and in vivo (Kuhn et al., 2002). 
IL-4/13 receptor activation is reported to 
be mandatory, but not sufficient, for the 
induction of 15-LO-1 expression in A549 
lung carcinoma cell line (Brinckmann et 
al., 1996). 
The cytokine induced upregulation of 
15-LO-1 gene requires expression of a 
signal transducer and activator of 
transcription (STAT) 6 (Heydeck et al., 
1998) and IL-4 dependent binding of 
STAT6 to the STAT6 response element 
in the 15-LO-1 promoter (Conrad et al., 
2000). A specific antibody against IL-13 
receptor α1 can inhibit IL-13 induced 15-
LO-1 expression and tyrosine 
phosphorylation of STAT6 (Krause et al., 
2006). Studies have shown that in 
addition to tyrosine phosphorylation of 
STAT6, also acetylation of both STAT6 
and histones is required. It has been 
suggested that in the absence of IL-4, 
nuclear histones may be bound to 
regulatory elements of the 15-LO-1 gene, 
preventing its transcription. IL-4 
stimulation causes rapid phosphorylation 
of STAT6, but its binding to the promoter 
appears to be prevented by 
nonacetylated histones. Once the 
histones have become acetylated, 
STAT6 binding sites may be unmasked 
so that the phosphorylated and 
acetylated transcription factor can bind 
and activate 15-LO-1 gene transcription 
(Shankaranarayanan et al., 2001). 
Translational regulation 
 
15-LO-1 mRNA is abundant in young 
rabbit reticulocytes as a translationally 
inactive free cytoplasmic messenger 
ribonucleoprotein particle, but functional 
enzyme is not expressed (Thiele et al., 
1982). The 15-LO-1 mRNA 3’ UTR 
contains a repeated sequence where 
regulatory proteins can bind, thus 
preventing translation (Fleming et al., 
1989; Ostareck-Lederer et al., 1994). 
This differentiation control element 
(DICE) of rabbit 15-LO-1 is composed of 
ten subunits, whereas the human 15-LO-
1 DICE has three repetitive structures 
(Reimann et al., 2002). The regulatory 
proteins binding to the repeats have been 
isolated and identified as heterogeneous 
nuclear ribonucleoprotein (hnRNP) K and 
E1, which cause inhibition of the 80S 
ribosome assembly on the 15-LO-1 
mRNA. More specifically, the 3’ UTR 
regulatory complex prevents joining of 
the 60S ribosomal subunit at the 
translation start codon, thus inhibiting the 
formation of the translation competent 
80S ribosome (Ostareck et al., 1997; 
Ostareck et al., 2001). 
Binding of the inhibitory proteins 
depends on the number of the repetitive 
structures. At least two repeat sequences 
of the DICE are required for translational 
inhibition by hnRNP E1 suggesting that 
the binding of at least two hnRNP E1 
molecules activates or exposes a binding 
site to allow the complex to interact with 
the 5’-end of the mRNA and to prevent 
translation (Reimann et al., 2002). 
Certain hnRNP K -homology domains of 
hnRNP E1 and K have been identified as 
the DICE -binding domains (Messias et 
al., 2006). 
Translational silencing of DICE-
bearing mRNAs can be overcome by a 
specific interaction with hnRNP K and c-
Src, leading to c-Src activation and 
tyrosine phosphorylation of hnRNP K. 
This phosphorylation reversibly inhibits 
the binding of hnRNP K to DICE and 
specifically activates translation of the 
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silenced mRNA (Ostareck-Lederer et al., 
2002).  
 
 
Posttranslational regulation 
 
There are no major posttranslational 
modifications of 15-LO-1 protein e.g. no 
evidence of glycosylation has been 
detected (Kühn et al., 1993a). 
 
 
Regulation of enzymatic activity 
 
Lipid hydroperoxides 
 
The catalytic activity of 15-LO-1 is 
highly regulated by several factors. The 
dioxygenase reaction by 15-LO-1 typically 
has a kinetic lag phase (Ludwig et al., 
1987). This can be abolished by addition 
of hydroperoxy fatty acids (Ludwig et al., 
1987; Schnurr et al., 1996), which oxidize 
the ferrous (Fe2+) nonheme iron into the 
ferric (Fe3+) form (de Groot et al., 1975). 
Mechanistic studies with soybean 15-LO 
have revealed that lipid hydroperoxides 
activate 15-LO by binding to the enzyme, 
facilitating its activation, but remaining 
chemically unchanged in this process 
(Jones et al., 1996). 
 
 
Nitric oxide 
 
Likewise, ˙NO is able to regulate the 
catalytic activity of 15-LO-1 by affecting 
the oxidation state of the nonheme iron. 
Short-term incubations of 15-LO-1 in the 
presence of ˙NO lead to a prolonged 
kinetic lag period, possibly due to the 
formation of a dissociable LO-˙NO 
complex, whereas long-term incubations 
shorten the lag phase by oxidizing the 
ferrous LO to a ferric form which is more 
susceptible to peroxide activation 
(Wiesner et al., 1996; Holzhütter et al., 
1997). 15-LO-1 affects the bioavailability 
of ˙NO and ˙NO signalling by catalytically 
consuming ˙NO and inhibiting the 
activation of the soluble guanylate 
cyclase (O'Donnell et al., 1999; Coffey et 
al., 2001). In fact, elevated plasma ˙NO 
metabolites and induced eNOS 
expression are detected in 12/15-LO 
knockout mice suggesting that 15-LO-1 
can affect the ˙NO bioavailability in vivo 
(Anning et al., 2005). 
 
 
Phospholipid hydroperoxide 
glutathione peroxidase 
 
Phospholipid hydroperoxide 
glutathione peroxidase (PHGPX) is the 
only known selenoperoxidase capable of 
reducing 15-LO-1 peroxidation products, 
i.e. hydroperoxy lipids esterified to 
biomembranes and lipoproteins (Thomas 
et al., 1990a; Thomas et al., 1990b; 
Schnurr et al., 1996). It also down-
regulates 15-LO-1 activity, probably by 
reducing the hydroperoxy lipids 
necessary for the activation of the 
lipoxygenase reaction (Schnurr et al., 
1996; Huang et al., 1999a), thus 
counteracting the effects of 15-LO-1. 
 
 
Calcium 
 
Calcium can modulate 15-LO-1 
activity in polymorphonuclear leukocytes 
(Nichols et al., 1991) and the calcium 
dependent association of 15-LO-1 to 
membranes stimulates 15-LO-1 activity 
(Watson et al., 1994; Brinckmann et al., 
1998; Hsi et al., 2001). Membrane 
association of 15-LO is primarily 
mediated via hydrophobic interactions 
between apolar amino acids and the 
hydrophobic core of membrane 
phospholipids, but calcium supports 
membrane binding probably by 
electrostatic forces (Walther et al., 2004). 
 
 
Self-inactivation 
 
15-LO-1 is irreversibly inhibited during 
oxygenation of polyenoic fatty acids by its 
product 13-HPODE resulting in suicidal 
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inactivation (Rapoport et al., 1979; Härtel 
et al., 1982; Kühn et al., 1993a). The self-
inactivation was originally suggested to 
involve oxygenation of a single 
methionine to methionine sulfoxide 
(Rapoport et al., 1984), but this kind of 
methionine oxidation was later shown not 
to be critical for enzyme inactivation (Gan 
et al., 1995). Instead, 15-LO-1 catalyzed 
conversion of 15-HPETE to 14,15-
epoxyleukotriene leads to the formation 
of reactive intermediates, which are 
capable of covalently binding to several 
active site amino acids and evoke the 
suicidal inactivation of the enzyme 
(Wiesner et al., 2003). 
 
 
15-LO-1 in atherosclerosis 
 
Lipoprotein oxidation and foam cell 
formation 
 
15-LO-1 can oxidatively modify LDL 
showing preferential oxygenation of LDL 
cholesterol esters (Belkner et al., 1993; 
Belkner et al., 1998) and phospholipids 
(Heydeck et al., 2001). Retrovirus 
mediated gene transfer studies also 
support the role of 15-LO-1 in LDL 
oxidation. Overexpression of 15-LO-1 in 
murine fibroblasts leads to enhanced 
levels of lipoperoxides in LDL incubated 
with these cells, detected especially in 
the cholesteryl esters (Benz et al., 1995; 
Ezaki et al., 1995). In addition, 12/15-LO 
deficient mouse macrophages have a 
decreased ability to form foam cells, 
when incubated with LDL (Huo et al., 
2004). However, in an in vitro foam cell 
model based on the uptake of acetylated 
LDL by murine macrophages, 12/15-LO 
attenuates the intracellular lipid 
deposition and degrades internalized LDL 
lipids more rapidly, suggesting that 
12/15-LO can impact on both lipid uptake 
and intracellular turnover (Belkner et al., 
2005). 
 
 
Adhesion molecule expression and 
monocyte adhesion 
 
Transient overexpression of 15-LO-1 
in bovine aortic ECs increases tumor 
necrosis factor (TNF) induced vascular 
cell adhesion molecule 1 (VCAM-1) 
expression (Wölle et al., 1996). Similarly, 
15-LO-1 and its reaction product 15-
HPETE induce adhesion molecule 
expression in ECs (Sultana et al., 1996; 
Sordillo et al., 2008) and 15-HPETE 
increases transendothelial migration of 
monocyte-like cells (Sultana et al., 1996). 
Fibroblasts overexpressing 15-LO-1 
generate bioactive, minimally oxidized 
LDL, which stimulates monocyte 
chemotaxis and adhesion to ECs (Sigari 
et al., 1997; Lee et al., 1999). In the 
presence of LDL, macrophage 12/15-LO 
induces monocyte adhesion to ECs by 
activating ECs and upregulating VCAM-1 
expression (Huo et al., 2004). Inhibition 
studies with short hairpin RNA to knock 
down the endogenous 12/15-LO 
expression in mouse macrophages and 
rat and mouse vascular SMCs have been 
shown to reduce oxidant stress, reduce 
chemokine and VCAM-1 expression, and 
reduce the monocyte adhesion to the 
SMCs (Li et al., 2005). 
Production of 12/15-LO metabolites is 
induced in diabetic db/db mice. Monocyte 
adhesion to ECs derived from these mice 
is increased. The increase in adhesion 
can be reduced by inhibiting 12/15-LO 
using either an adenovirus expressing a 
ribozyme to 12/15-LO or with the 12/15-
LO inhibitor, cinnamyl-3,4-dihydroxy-α-
cyanocinnamate. The adhesion is 
mediated by the interactions of monocyte 
integrins with endothelial VCAM-1, 
connecting segment 1 fibronectin and 
intercellular adhesion molecule 1 (ICAM-
1) (Hatley et al., 2003). Increased 
monocyte adhesion is mediated by these 
same factors also in ECs isolated from 
12/15-LO transgenic mice, where ICAM-1 
expression is induced severalfold (Reilly 
et al., 2004) via activation of nuclear 
factor kappa B (NF-κB) by the 12/15-LO 
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reaction product 12(S)-HETE (Bolick et 
al., 2005). On the contrary, in 
apolipoprotein E (apoE)/12/15-LO double 
knock-out mice NF-κB activation, ICAM-1 
induction and monocyte adhesion to 
aortic endothelium are reduced as 
compared to the apoE knock-out control 
mice (Bolick et al., 2006). 
In vascular SMCs, 13-HPODE 
activates NF-κB as well as VCAM-1 
transcription (Natarajan et al., 2001). 
12/15-LO overexpression in vascular 
SMCs induces VCAM-1 expression and 
the induction is prevented by inhibiting 
NF-κB (Dwarakanath et al., 2008). 
However, in another study it has been 
shown that both PHGPX and 15-LO-1 
overexpressions inhibit basal and IL-1 
induced VCAM-1 expression. It has been 
suggested that constitutive 
overproduction of hydroperoxides can 
inhibit VCAM-1 expression by rendering 
the cells refractory to IL-1 stimulation, 
possibly by oxidizing protein thiols of the 
signalling system (Banning et al., 2004). 
Overexpression of 12/15-LO can 
enhance growth factor induced binding of 
monocytes to vascular SMCs, whereas 
monocyte binding is reduced to vascular 
SMCs derived from 12/15-LO knockout 
mice (Cai et al., 2004). 
 
 
15-LO-1 expression in atherosclerotic 
lesions 
 
15-LO reaction products are produced 
by atherosclerotic rabbit aortas when 
incubated with AA (Henriksson et al., 
1985; Simon et al., 1989; Hugou et al., 
1995). mRNA and protein expression of 
15-LO-1 are detected in rabbit and 
human atherosclerotic lesion 
macrophages colocalizing with oxidatively 
modified lipid products (Ylä-Herttuala et 
al., 1990; Ylä-Herttuala et al., 1991; 
Hiltunen et al., 1995; Hugou et al., 1995). 
15-LO-1 mRNA expression is also 
detected in ECs and SMCs of rabbit 
atherosclerotic lesions (Ylä-Herttuala et 
al., 1990; Hugou et al., 1995). Specific 
15-LO-1 oxidation products can be 
detected in lipids extracted from rabbit 
and human atherosclerotic lesions (Kühn 
et al., 1994; Folcik et al., 1995; Kühn et 
al., 1997). The induction of 15-LO-1 
mRNA and specific 15-LO-1 reaction 
products are most prominent in early 
atherosclerotic lesions (Kühn et al., 1994; 
Hiltunen et al., 1995; Kühn et al., 1997). 
15-LO-1 protein has also been detected 
in complex atheromatous lesions of 
transplant coronary artery disease 
(Ravalli et al., 1995a; Ravalli et al., 
1995b). 
In vivo gene transfer of 15-LO-1 into 
rabbit iliac arteries induces the 
appearance of lipid-protein adducts 
characteristic of oxidized LDL (Ylä-
Herttuala et al., 1995), whereas treatment 
with a specific 15-LO-1 inhibitor limits the 
progression of atherosclerosis in rabbits 
(Sendobry et al., 1997; Bocan et al., 
1998). 
 
 
Phenotypes of transgenic 15-LO-1 
animals 
 
LDL receptor (LDLR) knockout mice 
created by homologous recombination in 
embryonic stem cells (Ishibashi et al., 
1993) develop hypercholesterolemia and 
complex atherosclerotic lesions when fed 
with a high-fat diet (Ishibashi et al., 
1994). 15-LO-1 overexpression in LDLR-
deficient mice under preproendothelin-1 
promoter accelerates early 
atherosclerosis. These LDLR-/-/15-LO 
transgenic mice express 15-LO-1 protein 
in aortic sinuses and the induced 15-LO-
1 enzyme activity is detected in trachea, 
heart and aorta. LDL isolated from these 
mice is more susceptible to oxidation 
than the LDL from the control LDLR-/- 
mice (Harats et al., 2000). 12/15-LO 
transgenic mice also develop 
atherosclerosis (Reilly et al., 2004). 
In contrast, 15-LO-1 transgenic 
rabbits expressing 15-LO-1 specifically in 
macrophages (Shen et al., 1995) have 
smaller atherosclerotic lesions than their 
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nontransgenic littermates (Shen et al., 
1996). 15-LO-1 transgenic mice have 
also been created in conjunction with the 
apoE knockout background. ApoE 
knockout mice were created by 
homologous recombination in embryonic 
stem cells (Piedrahita et al., 1992; Plump 
et al., 1992). These animals develop 
marked hypercholesterolemia and 
extensive atherosclerosis on both low 
and high fat diet (Plump et al., 1992; 
Zhang et al., 1992). Similarly to the 
transgenic rabbits, macrophage-specific 
overexpression of 15-LO-1 under 
scavenger receptor promoter in apoE 
knockout mouse background protects 
against the development of 
atherosclerosis in aorta (Merched et al., 
2008). 
 
 
Phenotypes of 12/15-LO knock-out 
mice 
 
12/15-LO knockout mice were created 
by homologous recombination in 
embryonic stem cells (Sun et al., 1996). 
Atherogenesis is decreased in double-
knockout mice created by crossbreeding 
the 12/15-LO knockout mice with apoE 
deficient mice (Cyrus et al., 1999; Cyrus 
et al., 2001; Zhao et al., 2005; Tang et 
al., 2008) or LDLR knockout mice 
(George et al., 2001). Atherosclerosis is 
also reduced in triple-knockout mice 
created by crossbreeding the 12/15-LO 
knockout mice with Apobec-/-/LDLR-/- 
double-knockouts (Zhao et al., 2002), 
which is a mouse model of human 
familial hypercholesterolemia (Powell-
Braxton et al., 1998). Decreased lipid 
peroxidation and autoantibodies against 
oxidized LDL have been detected in the 
12/15-LO-apoE double knockout mice 
(Cyrus et al., 2001; Tang et al., 2008). 
The involvement of 12/15-LO in the 
development of atherosclerosis was 
examined in a study, where bone marrow 
cells from 12/15-LO-apoE double-
knockout (12/15-LO-/-/apoE-/-) mice were 
transplanted into apoE-/- mice coferring 
protection from atherosclerosis, whereas 
conversely transplantation of apoE-/- bone 
marrow cells into 12/15-LO-/-/apoE-/- mice 
resulted in the more severe development 
of atherosclerosis typically detected in 
apoE-/- mice (Huo et al., 2004). 
As with the transgenic mouse models, 
contradictory results about the role of 
12/15-LO in atherogenesis have also 
been presented with 12/15-LO knockout 
mice. Lack of 12/15-LO accerelates 
atherosclerosis in 12/15-LO-/-/apoE-/- 
double knockouts compared to the 
control apoE-/- mice (Merched et al., 
2008). In addition, opposing 
atheroprotective results have also been 
obtained with bone marrow cell 
transplantations. Transplantation of bone 
marrow cells from 12/15-LO+/+/apoE-/- 
donors to 12/15-LO-/-/apoE-/- double 
knockouts leads to smaller lesion size 
than transplantation of the 12/15-LO-/-
/apoE-/- bone marrow back to the original 
12/15-LO-/-/apoE-/- donor. This is 
considered to reflect an atheroprotective 
effect of 12/15-LO, which is believed to 
be mediated by local biosynthesis of lipid 
mediators, including lipoxin A4, resolvin 
D1 and protectin D1. These mediators 
can resolve the local inflammatory 
response on macrophages and vascular 
ECs (Merched et al., 2008). 
 
 
15-LO-1 and angiogenesis 
 
Very little is known about the effects 
of 15-LO-1 on angiogenesis. Both anti- 
and pro-angiogenic roles for 15-LO-1 
have been presented. 
Transgenic mice overexpressing 15-
LO-1 in the vascular wall under the 
preproendothelin-1 promoter (Harats et 
al., 1995) have been used to test the 
effects of the vascular overexpression of 
15-LO-1. In the Lewis lung carcinoma 
model, the lung metastases of the 15-LO-
1 transgenic mice contain an extensive 
hemorrhagic necrotic core, a higher 
number of apoptotic cells and also 
multiple small blood vessels arranged in 
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a complicated network (Harats et al., 
2005). Recently, an anti-angiogenic 15-
LO-1 metabolite, 15-oxo-eicosatetraenoic 
acid, has been identified. 15-Oxo-
eicosatetraenoic acid inhibits EC 
proliferation by suppressing 
deoxyribonucleic acid (DNA) synthesis 
(Wei et al., 2009). 
Hypoxia studies with human retinal 
microvascular ECs have shown that 
hypoxia can induce 15-LO-1 expression 
and the production of 15(S)-HETE, which 
in turn stimulates EC migration and tube 
formation (Bajpai et al., 2007). PC-3 
prostate cancer cells stably 
overexpressing 15-LO-1 have been 
generated by plasmid transfection and 
selection for antibiotic resistance. These 
cells have elevated VEGF secretion and 
increased proliferation compared with the 
controls (Kelavkar et al., 2001). 
 
 
15-LO-1, apoptosis and 
tumorigenesis 
 
The selenoenzyme thioredoxin 
reductase is an important regulator of the 
redox balance within cells (Arnér and 
Holmgren, 2000). 15-LO-1 metabolites 
inhibit thioredoxin reductase, cause cell 
cycle arrest at the G1 phase and induce 
the pro-apoptotic BAX protein (Yu et al., 
2004). Depletion of PHGPX, the only 
known glutathione peroxidase capable of 
reducing phospholipid hydroperoxides 
(Thomas et al., 1990a; Thomas et al., 
1990b) results in early embryonic lethality 
(Yant et al., 2003). In order to study the 
molecular and cellular mechanisms of 
PHGPX, a conditional, inducible PHGPX 
knockout mouse has been created. 
Depletion of PHGPX in these mice 
causes massive lipid peroxidation and 
cell death. These events require 
functional 12/15-LO and are mediated by 
apoptosis-inducing factor (Seiler et al., 
2008). 
13-HODE and enzymatic modification 
of LDL with 15-LO-1 induce apoptosis in 
monocytic cells (Jostarndt et al., 2002), 
and enhanced 15-HPETE production or 
induced 15-LO-1 expression increases 
apoptosis (Sordillo et al., 2005; Kim et al., 
2006) by activation of caspase-3 and -9 
(Sordillo et al., 2005). Overexpression of 
15-LO-1 in the vascular endothelium of 
LDLR knock-out mice is associated with 
increased thymic apoptosis, which is 
mediated by caspase-3 (Afek et al., 
2004). 
Rather conflicting results have been 
obtained from the cancer studies, with 
evidence for either pro- or anti-apoptotic, 
and pro- or anti-tumorigenic role for 15-
LO-1, depending on the tumor and tissue 
type. Transgenic mice overexpressing 
15-LO-1 in the vascular wall under the 
preproendothelin-1 promoter (Harats et 
al., 1995) have been used in two different 
tumor models to test the effects of the 
vascular overexpression of 15-LO-1. 15-
LO-1 significantly reduces the growth of 
lung metastases in the Lewis lung 
carcinoma model and significantly 
increases the survival of the animals. In a 
mouse mammary adenocarcinoma 
model, the development of primary 
tumors is prevented in the 15-LO-1 
transgenic mice (Harats et al., 2005).  
The evidence points to strikingly 
different roles for 15-LO-1 in colorectal 
and prostate cancer. The studies 
implying an anti-tumorigenic role in 
colorectal cancer and a pro-tumorigenic 
role in prostate cancer will be reviewed in 
detail in the following chapters. 
 
 
15-LO-1 in colorectal cancer 
 
15-LO-1 expression is decreased in 
colorectal cancer cell lines (Shureiqi et 
al., 1999). The 15-LO-1 products 13-
HODE and 15-HETE can suppress cell 
proliferation and induce apoptosis in 
colorectal cancer cell lines in vitro 
(Shureiqi et al., 1999; Chen et al., 2003; 
Nixon et al., 2004), as does also ectopic 
restoration of 15-LO-1 activity (Shureiqi 
et al., 2005). 
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The earliest report about 15-LO-1 
expression in human colorectal cancer 
tissues stated that 15-LO-1 is highly 
expressed in colorectal carcinoma 
epithelial cells (Ikawa et al., 1999). 
However, further studies have indicated 
that 15-LO-1 expression and 13-HODE 
and 15-HETE production are decreased 
in human colon cancers (Shureiqi et al., 
1999; Chen et al., 2003; Heslin et al., 
2005; Shureiqi et al., 2005; Zuo et al., 
2009), and the reduced 15-LO-1 
expression is associated with poorer 
overall survival in the patients with stage 
IV colorectal cancer (Heslin et al., 2005). 
It has been suggested that reversal of 
expression of 15-LO-1 to 
cyclooxygenase-2 is associated with the 
development of colon cancer. 15-LO-1 
mRNA expression is mostly detected in 
low-grade adenomas and not found in 
advanced carcinoma, whereas 
cyclooxygenase-2 protein production is 
detected mostly in invasive carcinomas. 
Significant concurrent down-regulation of 
15-LO-1 and up-regulation of 
cyclooxygenase-2 are detected in 
invasive carcinomas (Yuri et al., 2007). 
In the athymic nude mouse xenograft 
model, subcutaneously transplanted 
tumors derived from 15-LO-1 
overexpressing HCT-116 colorectal 
carcinoma cells are smaller than tumors 
derived from the control HCT-116 cells 
(Nixon et al., 2004). Adenoviral 15-LO-1 
gene transfer induces a therapeutic effect 
in colon cancer. 15-LO-1 expression 
downregulates the expression of anti-
apoptotic proteins, activates caspase-3, 
induces apoptosis, and inhibits colon 
cancer cell survival in vitro. Local 15-LO-
1 adenovirus injections into 
subcutaneously transplanted colon 
cancer xenografts in vivo in nude mice 
are able to inhibit the growth of the 
xenografts (Wu et al., 2008). 
Induction by non-steroidal anti-
inflammatory drugs 
 
Non-steroidal anti-inflammatory drugs 
(NSAID), potential chemopreventive 
agents, have been shown to stimulate the 
15-LO-1 pathway in human 
polymorphonuclear leukocytes 
(Vanderhoek et al., 1984). NSAIDs also 
induce 15-LO-1 protein expression and 
enzymatic activity in colorectal cancer cell 
lines. This is associated with reduced cell 
growth and increased cell apoptosis 
(Shureiqi et al., 2000a; Shureiqi et al., 
2000b; Heslin et al., 2005). These effects 
are prevented by inhibiting 15-LO-1 and 
restored by adding exogenous 15-LO-1 
reaction product 13-HODE (Shureiqi et 
al., 2000a; Shureiqi et al., 2000b). In 
addition, NSAID-induced apoptosis is 
increased in colorectal carcinoma cells 
overexpressing 15-LO-1 or treated with 
13(S)-HODE (Yoshinaga et al., 2007). 
NSAIDs induce 15-LO-1 expression 
and concomitant apoptosis in colorectal 
carcinoma cell lines at the transcriptional 
level by down-regulating the expression 
of GATA-6, a transcription factor that 
suppresses 15-LO-1 expression 
(Shureiqi et al., 2002). GATA-6 mRNA 
and protein expression are induced in 
colon cancer and inhibition of GATA-6 
expression combined with NSAID 
restores 15-LO-1 expression and induces 
apoptosis in colon cancer cells (Shureiqi 
et al., 2007). Participants are currently 
being recruited to a phase II clinical trial, 
where the primary objective is to 
determine whether the NSAID celecoxib 
can downregulate GATA-6 expression to 
upregulate 15-LO-1 expression and to 
induce apoptosis in human rectal tumors 
(U. S. National Institutes of Health, 
http://www.clinicaltrials.gov, accessed 
October 2009). 
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Induction by histone deacetylase 
inhibitors 
 
Histone deacetylases (HDAC) are 
important epigenetic regulators of gene 
expression. They mediate changes in 
nucleosome conformation by 
deacetylating histones, which leads to 
chromatin compaction and transcriptional 
repression. HDAC inhibitors are involved 
in growth arrest, cell differentiation, 
cytotoxicity and induction of apoptosis (de 
Ruijter et al., 2003), and have therefore 
emerged as potential therapeutic agents 
in the treatment of cancer (Marks et al., 
2001). Currently, there are almost a 
hundred clinical trials listed for the 
treatment of different cancers with HDAC 
inhibitors (U. S. National Institutes of 
Health, http://www.clinicaltrials.gov, 
accessed October 2009). 
Interestingly, HDAC inhibitors induce 
15-LO-1 expression in colorectal 
carcinoma cell lines by stimulating 15-
LO-1 promoter activity (Kamitani et al., 
1998; Kamitani et al., 2001; Hsi et al., 
2004; Shureiqi et al., 2005; Zuo et al., 
2008a; Zuo et al., 2009). The induced 15-
LO-1 expression correlates with 13(S)-
HODE production, growth inhibition, 
differentiation and apoptosis in these cell 
lines (Kamitani et al., 1998; Hsi et al., 
2004; Shureiqi et al., 2005; Zuo et al., 
2009). 
As with NSAIDs, down-regulation of 
GATA-6 expression combined with an 
HDAC inhibitor restores 15-LO-1 
expression and induces apoptosis in 
colon cancer cell lines (Shureiqi et al., 
2007). Histone acetylation correlates with 
15-LO-1 expression both in colorectal 
carcinoma cells and in colorectal tissue 
suggesting a role for histone acetylation 
in the regulation of 15-LO-1 expression in 
colorectal carcinoma (Kamitani et al., 
2001). The acetylation of histones H3 
and H4 by histone acetyltransferase 
KAT3B is critical for 15-LO-1 
transcriptional activation, independently 
from STAT6 (Zuo et al., 2008a). A recent 
report has shown that recruitment of the 
nucleosome remodelling and histone 
deacetylation repression complex to 15-
LO-1 promoter can repress 15-LO-1 
transcription, whereas a specific HDAC1 
and HDAC2 inhibitor restores 
transcription. Transcriptional 
downregulation of the essential 
repression complex components induces 
15-LO-1 transcription (Zuo et al., 2009). 
 
 
Induction by methyltransferase inhibitors 
 
In addition to histone deacetylation, 
DNA methylation is another important 
epigenetic mechanism involved in 
regulating gene expression (Jones et al., 
2001). Hypermethylation of tumor 
suppressor genes by DNA 
methyltransferases is often encountered 
in many human cancers (Mund et al., 
2006). Similarly to NSAIDs and HDAC 
inhibitors, also methyltransferase 
inhibitors induce 15-LO-1 expression in 
colorectal cancer cell lines and this leads 
to increased 13(S)-HODE production, 
growth inhibition and apoptosis (Hsi et 
al., 2005). A specific 15-LO-1 promoter 
demethylation is necessary for HDAC 
inhibitor mediated activation of 15-LO-1 
transcription (Zuo et al., 2008a). 
Transcriptional activation of 15-LO-1 by 
HDAC inhibitor can be suppressed by 
DNA methyltransferase 1 binding to the 
15-LO-1 promoter without affecting 
promoter methylation (Zuo et al., 2008b). 
 
 
Role of peroxisome proliferator-activated 
receptors 
 
Peroxisome proliferator-activated 
receptors (PPAR) are nuclear receptors 
that have been linked to adipocyte 
differentiation (Chawla et al., 1994) and 
the control of cellular lipid uptake 
(Tontonoz et al., 1998). The 15-LO-1 
products 13-HODE and 15-HETE are 
endogenous activators and ligands of 
PPAR-γ (Nagy et al., 1998; Huang et al., 
1999b). Treatment of colon cancer cells 
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with 15(S)-HETE inhibits cell proliferation 
and viability and induces apoptosis via a 
PPAR-γ dependent pathway (Chen et al., 
2003).  
PPAR-δ deficiency decreases colon 
tumorigenesis (Park et al., 2001) and 
NSAIDs suppress the activity of PPAR-δ 
in colon cancer cells (He et al., 1999a). 
13-HODE binds to PPAR-δ leading to 
decreased expression and activation of 
PPAR-δ in colorectal cancer cells. 
Induction of 15-LO-1 is a critical step in 
the NSAID mediated suppression of 
PPAR-δ activity and the resultant 
induction of apoptosis. The in vivo 
relevance of this mechanism has been 
demonstrated in nude mouse xenograft 
model, where NSAID reduced the tumor 
growth and down-regulated PPAR-δ 
protein expression, but these effects 
were prevented, when 15-LO-1 
expression was blocked (Shureiqi et al., 
2003). 
The interplay between 15-LO-1 and 
PPARs β, δ and γ has been further 
evaluated in colon cancer cells. The 15-
LO-1 metabolite 13(S)-HODE mediates 
the activation of PPAR-γ by 
downregulating PPARs β and δ, resulting 
in the induction of apoptosis (Zuo et al., 
2006). 
 
 
15-LO-1 in prostate cancer 
 
Human prostate tumors and prostate 
cancer cell lines express 15-LO-1 and 
produce the 15-LO-1 metabolite 13-
HODE (Spindler et al., 1997; Kelavkar et 
al., 2000). 15-LO-1 mRNA expression is 
significantly higher in human prostate 
cancer tissue when compared to normal 
prostate tissue (Kelavkar et al., 2006a). 
The intensity of 15-LO-1 immunostaining 
correlates with the degree of malignancy 
(Kelavkar et al., 2000). Similarly, 
expression and activity of 12/15-LO are 
induced in transgenic mouse models of 
prostate carcinoma, and the expression 
increases with the progression of the 
disease (Shappell et al., 2003; Kelavkar 
et al., 2004). In the FLiMP mouse model, 
where 15-LO-1 is expressed in the 
luminal epithelial cells of adult mice, the 
conditional expression of 15-LO-1 is 
sufficient to promote epithelial 
proliferation and prostatic intraepithelial 
neoplasia (Kelavkar et al., 2006b). The 
same effect is also seen with adenovirus 
mediated 15-LO-1 gene transfer into 
mouse prostate tissue (Sen et al., 2006). 
Stable overexpression of 15-LO-1 in 
human prostate cancer cells increases 
cell proliferation and subcutaneous 
inoculation of the 15-LO-1 
overexpressing cells into nude mice 
evokes an increase in the frequency of 
tumor formation, tumor size and tumor 
angiogenesis suggesting a growth 
promoting role for 15-LO-1 in the prostate 
(Kelavkar et al., 2001). 
Epigenetic regulation for 15-LO-1 
expression has also been shown in 
prostate cancer, where hypermethylation 
of a specific CpG dinucleotide in the 15-
LO-1 promoter leads to upregulation of 
15-LO-1 expression and enzyme activity 
and contributes to prostate cancer 
initiation and progression. In contrast to 
the situation in colon cancer cells, 
combination treatment with DNA 
methyltransferase inhibitor and HDAC 
inhibitor reduces 15-LO-1 expression in 
prostate cancer cells (Kelavkar et al., 
2007). 
STAT6, a transcriptional activator of 
15-LO-1, is highly expressed in prostate 
cancer tissues. Down-regulation of 
STAT6 in prostate cancer cell lines in 
vitro leads to decreased 15-LO-1 
expression, induction of apoptosis, 
inhibition of cell migration, reduced cell 
viability and transcriptional down-
regulation of anti-apoptotic  Bcl-XL protein 
(Das et al., 2007). 
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VIRAL GENE TRANSFER 
VECTORS 
 
Viruses have been exploited in gene 
expression studies and applied to gene 
therapy due to their natural capabilities 
for transferring genetic material into 
eukaryotic cells. The viral vectors used in 
gene therapy are generally modified in 
such a way that they lose their ability to 
multiply in all other cells except 
genetically modified packaging cells, 
which are used for the production of the 
replication-incompetent recombinant 
viruses. 
The first viral vectors used for gene 
therapy were retroviral vectors based on 
murine leukemia virus (oncoretrovirus). 
Currently, the adenoviral vectors have 
become the most widely used virus 
derived vectors (Figure 5). In addition to 
retro- and adenoviral vectors, several 
other virus-derived gene transfer vectors 
have been developed. They are reviewed 
in the following chapters and summarized 
in Table II.
Adenovirus 24 %
Retrovirus 20.9 %
Naked/Plasmid DNA 17.9 %
Vaccinia virus 7.9 %
Lipofection 6.9 %
Poxvirus 5.8 %
Adeno-associated virus 4.3 %
Herpes simplex virus 3.2 %
RNA transfer 1.4 %
Other categories 4.5 %
Unknown 3.2 %
 
Figure 5. Vectors used in gene therapy trials. According to Journal of Gene Medicine, 
http://www.wiley.co.uk/genmed/clinical, accessed October 2009. 
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Retrovirus vectors 
 
Oncoretroviruses 
 
Retrovirus particles consist of a viral 
protein core, which is surrounded by an 
envelope made up of cellular membrane-
derived lipid bilayer and viral-encoded 
glycoproteins. Oncoretroviruses have two 
copies of a single stranded RNA 
genome, which contains genes gag, pol 
and env encoding the viral structural and 
catalytic proteins. Gag encodes the viral 
core proteins (matrix, capsid and 
nucleocapsid), pol encodes the viral 
replication enzymes (protease, reverse 
transcriptase and integrase) and env 
encodes the envelope glycoprotein. 
During virus replication, the RNA is 
reverse transcribed into an intermediate 
double stranded DNA, which integrates 
randomly into the target cell DNA as a 
provirus having long terminal repeats 
(LTR) at each end of the proviral 
genome. The 5’ LTR contains the viral 
promoter and enhancers, whereas the 3’ 
LTR contains the transcription 
termination signal. During the virus 
replication cycle, full-length transcripts of 
the viral genome, which contain the 
packaging signal, are packaged into virus 
particles assembled from the newly 
synthesized structural proteins. The virus 
particles bud off from the surface of the 
target cell and their tropism depends on 
which glycoproteins they carry in their 
envelope (Varmus, 1988; Sinn et al., 
2005). 
Oncoretroviral vectors encode the 
gene of interest between the viral LTR’s, 
whereas the viral structural proteins are 
supplied by a packaging cell line stably 
expressing these genes. The resulting 
recombinant oncoretroviruses carry and 
integrate the gene of interest into the 
target cell genome leading to stable 
expression of the transgene, but without 
further virus propagation (Buchschacher, 
2001). 
Retroviral vectors derived from 
oncoretroviruses are able to transduce 
only dividing cells, since they lack a 
nuclear transport function (Lewis et al., 
1994). The most important limitations of 
oncoretroviral vectors in gene therapy are 
their limited transduction efficiency and 
the potential production of replication 
competent viruses, as well as the 
possibility of integration into important 
genome sites, which could lead to 
deleterious effects, e.g. inactivation of a 
tumor suppressor or activation of an 
oncogene. (Sinn et al., 2005). 
 
Lentiviruses 
 
Lentiviruses belong to the class of 
retroviruses, but they have a more 
complex genome than the simple 
oncoretroviruses. Due to their genome 
complexity, lentiviruses have some 
benefits over the oncoretroviruses with 
regard to gene therapy. Unlike 
oncoretroviruses, lentiviruses can 
transduce also non-dividing cells. The 
most widely used lentivirus vectors are 
based on human immunodeficiency virus 
1, due to the fact that the structure and 
biology of this virus have been 
extensively studied ever since acquired 
immunodeficiency syndrome was found 
to be caused by this virus (Varmus, 1988; 
Sinn et al., 2005). 
In order to prevent the formation of 
replication competent retroviruses, the 
lentiviral vectors have been extensively 
modified. The lentiviral vector plasmids 
contain the transgene expression 
cassette and a minimal amount of viral 
sequences, i.e sequences required for 
the transfer and expression of the 
transgene into target cells. Virus 
sequences required for the packaging of 
viral particles are supplied by additional 
plasmids (Sinn et al., 2005). 
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Adenovirus vectors 
 
Adenoviruses cause mild respiratory, 
gastrointestinal, and ocular diseases. 
There are more than 50 human 
adenovirus serotypes, of which the most 
widely used in gene therapy studies are 
serotypes 2 and 5. 
Adenoviruses are non-enveloped 
icosahedral viruses about 70-90 nm in 
diameter. They have a protein coat, 
which shields the inner nucleoprotein 
core containing a linear double-stranded 
DNA genome of approximately 36 kb. 
The major structural protein of the capsid 
is a trimeric hexon protein. The vertices 
of the capsid consist of penton bases, 
which anchor the fiber proteins, whose 
knobs are the primary protein moieties 
responsible for the attachment of the 
virus to the coxsackievirus B and 
adenovirus receptor on the host cell. Cell 
surface integrins binding to the penton 
base mediate the internalization of the 
virus by receptor-mediated endocytosis. 
The inverted terminal repeats (ITR) at 
each end of the viral genome serve as 
the origins of DNA replication. The 
adenovirus genome is divided into early 
and late genes, referring to genes that 
are transcribed early, i.e. before viral 
DNA replication, and genes that are 
transcribed late, i.e. after the onset of 
viral DNA replication. 
Adenoviruses are able to transduce a 
wide variety of eukaryotic cells, both 
quiescent and actively dividing. However, 
the expression of the therapeutic gene is 
transient, since adenoviral genome does 
not integrate into the host cell genome, 
but remains extrachromosomal. The 
most important limitations of 
adenoviruses in gene therapy are the 
immune response and inflammatory 
reactions they cause in their host cells 
(McConnell et al., 2004; Goncalves et al., 
2006). 
Adeno-associated virus vectors 
 
Native adeno-associated viruses 
(AAV) are small (25 nm) single-stranded 
DNA viruses of the parvovirus family. 
Their genome of approximately 5 kb is 
packaged into an icosahedral, non-
enveloped capsid and it contains two 
open reading frames between ITRs. The 
rep open reading frame codes for a 
family of multifunctional non-structural 
proteins (Rep) involved in viral genome 
replication, transcriptional control, 
integration and encapsidation of AAV 
genomes into preformed capsids. The 
cap open reading frame codes for the 
three capsid proteins VP1, VP2 and VP3, 
which differ in their N-terminus and thus 
define the specificity towards cellular 
receptors and the tissue tropism of the 
different AAV serotypes. The ITRs serve 
as origin of replication and play a key role 
in viral integration into the host cell 
genome (Büning et al., 2008; Daya et al., 
2008). Most recombinant AAV vectors 
are based on AAV-2, which enters the 
host cell by using the receptor heparan 
sulphate proteoglycan. The extent of 
internalization is enhanced by several 
coreceptors (Daya et al., 2008). 
The most important benefits of AAVs 
as gene therapy vectors are their non-
pathogenicity to humans and fairly low 
immunogenicity. AAV vectors are able to 
transduce both dividing and quiescent 
cells and even though they remain 
extrachromosomal, long-term gene 
expression is achieved. The major 
drawback of the AAV vectors for gene 
therapy purposes is their cumbersome 
production procedure, which is extremely 
difficult to scale up. In addition, since 
their productive infection requires the 
presence of a helper virus, production of 
helper virus free recombinant AAVs is 
difficult (Büning et al., 2008; Daya et al., 
2008). 
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Baculovirus vectors 
 
Baculoviruses are large, rod-shaped 
insect viruses with a double-stranded 
circular DNA genome. Due to their large 
packaging capacity, they have been 
widely used in biotechnology for protein 
production in insect cells. Baculoviruses 
are non-pathogenic to humans and 
efficiently transduce both dividing and 
quiescent cells. They can achieve 
transient gene expression, since they do 
not integrate into the host genome. Their 
construction and production in large 
quantities are relatively easy, and due to 
their large genome size, they can 
accommodate large transgenes (Airenne 
et al., 2009).
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AIMS OF THE STUDY 
 
 
The aims of the study were to explore the role of 15-LO-1 in the development of 
atherosclerosis, and in angiogenesis and tumorigenesis, by using retro- and adenovirus 
mediated gene transfer techniques both in vitro and in vivo. 
 
In more detail, the specific aims of the study were: 
 
I Create eukaryotic cells over-expressing 15-LO-1 by retro- and adenovirus mediated gene 
transfer methods in vitro, study the mRNA and protein expression as well as biological 
activity of 15-LO-1 in the transduced cells, and examine what kinds of gene expression 
changes are induced by 15-LO-1 over-expression. 
 
II Study the effects of 15-LO-1 on VEGF family mediated induction of angiogenesis by 
adenovirus mediated intramuscular gene transfer into rabbit hindlimb skeletal muscle. 
 
III Investigate the effects of 15-LO-1 in VEGF-A165 mediated induction of angiogenesis in a 
rabbit eye model by intravitreous adenovirus mediated gene transfer. 
 
IV Examine the effects of 15-LO-1 overexpression in mouse by adenovirus mediated gene 
transfer via the tail vein and the effects of 15-LO-1 in a rat malignant glioma model.
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MATERIALS AND 
METHODS 
 
 
CELL CULTURE (I-IV) 
 
The cell lines and culture conditions 
used in this study are summarized in 
Table III. 
 
 
PRODUCTION OF 
RETROVIRUSES AND 
RETROVIRAL 
TRANSDUCTIONS (I) 
 
Transfections and transductions for 
retrovirus production were performed as 
described (Ausubel et al., 1992). 
Retroviral vectors pLZRNL (Sharkey et 
al., 1990; Ylä-Herttuala et al., 1995) and 
pLLORNL (Benz et al., 1995; Ylä-
Herttuala et al., 1995) code for the 
Escherichia coli β-galactosidase (Kalnins 
et al., 1983) and human 15-LO-1 (Sigal et 
al., 1988), respectively, under the LTR of 
Moloney murine leukemia virus. The 
vectors also contain Tn5 neomycin 
phosphotransferase gene expressed 
from an internal Rous sarcoma virus 
promoter for selection of clones resistant 
to the neomycin analog geneticin. 
Ecotropic retroviruses were produced in 
the Ψ2 packaging cell line by calcium 
phosphate transfection, concentrated by 
polyethylene glycol precipitation or by 
centrifugation, and used to transduce the 
amphotropic PA317 packaging cells. 
Stably transduced geneticin-resistant 
PA317 clones were isolated, expanded 
and analyzed for 15-LO-1 mRNA 
production, protein expression and 
enzymatic activity. Concentrated 
amphotropic retroviruses from chosen 
clones were used to transduce ECV304 
cells. 
PRODUCTION OF 
ADENOVIRUSES (II-IV) 
 
Human 15-LO-1 cDNA (Sigal et al., 
1988) was digested at 2245 base pairs 
(bp) with BglII to dissect out part of the 3’ 
UTR and the polyA signal. This 
shortened cDNA fragment was 
subcloned into an expression vector 
containing human cytomegalovirus 
(CMV) immediate early I promoter and 
intron A with splicing signals, and bovine 
growth hormone transcription termination 
signals and polyA region. The expression 
cassette was subsequently subcloned 
into the BglII-site in the pAdBglII-vector 
(Barr et al., 1994) to produce pAd15-LO-
1 adenovirus vector. All recombinant 
adenoviruses used in this study and 
summarized in Table IV were produced 
in 293 cells by homologous 
recombination (Kozarsky et al., 1993). 
 
 
ADENOVIRAL 
TRANSDUCTIONS IN VITRO (II-
IV) 
 
In vitro adenoviral transductions were 
performed for rabbit abdominal aortic 
smooth muscle cells (RAASMC), primary 
human umbilical vein endothelial cells 
(HUVEC), ECV304 cells and RAW264.7 
mouse macrophages. Transductions 
were carried out under serum free 
conditions for 1 h. 
 
 
ADENOVIRAL GENE 
TRANSFERS IN VIVO (II-IV) 
 
All animal experiments described in 
the following sections were approved by 
the Experimental Animal Committee, 
University of Kuopio. 
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Table IV. Recombinant adenoviruses used in the study. 
 
Vector Description Application Publication 
in vitro, RAASMC and 
HUVEC; in vivo, 
intramuscular, rabbit 
hind limb skeletal 
muscle and the 
ischemia model 
II 
in vitro, ECV304 III 
AdlacZ 
Recombinant adenovirus 
containing E. coli β-galactosidase 
under CMV enhancer and chicken 
β-actin promoter 
in vitro, RAW264.7; in 
vivo, mouse tail vein IV 
in vitro, RAASMC and 
HUVEC; in vivo, 
intramuscular, rabbit 
hind limb skeletal 
muscle and the 
ischemia model 
II 
in vitro, ECV304; in vivo, 
rabbit intravitreous III 
Adh15-LO-1 
Recombinant adenovirus 
containing human 15-LO-1 under 
CMV promoter/enhancer with 
splice signals 
in vitro, RAW264.7; in 
vivo, mouse tail vein 
and rat glioma model 
IV 
in vitro, RAASMC and 
HUVEC; in vivo, 
intramuscular, rabbit 
hind limb skeletal 
muscle and the 
ischemia model 
II AdhVEGF-
A165 
Recombinant adenovirus 
containing human VEGF-A165 
under CMV promoter 
in vivo, rabbit 
intravitreous III 
AdmPlGF-2 
Recombinant adenovirus 
containing mouse PlGF-2 under 
CMV promoter 
in vivo, intramuscular, 
rabbit hind limb skeletal 
muscle 
II 
in vivo, intramuscular, 
rabbit hind limb skeletal 
muscle 
unpublished 
AdhVEGF-
D∆N∆C 
Recombinant adenovirus 
containing mouse interleukin 3 
signal sequence, flag-tag and the 
short mature form of human 
VEGF-D (VEGF-D∆N∆C) under 
CMV promoter 
in vivo, rabbit 
intravitreous unpublished 
AdCMV 
Recombinant adenovirus 
containing CMV promoter without 
any insert 
in vivo, rabbit 
intravitreous III 
 
 
 
Rabbit hind limb skeletal 
muscle (II) 
 
Intramuscular injections of 1.0 x 1011 
virus particles (vp) of each recombinant 
adenovirus (AdlacZ, Adh15-LO-1, 
AdhVEGF-A165, AdmPlGF-2, AdhVEGF-
D∆N∆C, and combinations of Adh15-LO-
1 with either AdhVEGF-A165, AdmPlGF-2 
or AdhVEGF-D∆N∆C [combination 
49 
groups]) in a total volume of 1 ml divided 
into ten separate 100 µl injections were 
performed into the semimembranosus 
thigh muscles. The animals were 
sacrificed six days after gene transfer, 
when the maximal gene transfer effects 
are known to be present (Rissanen et al., 
2003a). 
 
 
Rabbit hind limb ischemia 
model (II) 
 
Intramuscular injections of Adh15-LO-
1 and AdlacZ (1.0 x 1011 vp/ml) were 
performed into rectus femoris (5 x 100 
µl), gastrocnemius (5 x 100 µl) and 
tibialis anterior (5 x 100 µl) muscles. 
Three days after the gene transfers 
unilateral ischemia was induced by 
surgically removing the superficial 
femoral artery and ligating the deep 
femoral and lateral femoral circumflex 
arteries (Rissanen et al., 2002). The 
animals were sacrificed three days after 
the operations and samples were taken 
for immunohistochemistry. 
 
 
Rabbit intravitreal gene 
transfers (III) 
 
Intravitreal gene transfers were 
performed by injecting a total of 1.0 x 
1011 vp (AdCMV, Adh15-LO-1, 
AdhVEGF-A165 or AdhVEGF-D∆N∆C, 
and a combination of Adh15-LO-1 with 
AdhVEGF-A165 or AdhVEGF-D∆N∆C 
[treatment group]) in a total volume of 
100 µl (Kinnunen et al., 2006). 
Rabbit eyes were photographed 
before the gene transfers and one day 
before sacrifice with a digital fundus 
camera (Zeiss, FF450 PLUS IR, Jena, 
Germany). Photographs were taken from 
the anterior parts. Funduses were 
evaluated by a slit lamp and 
ophthalmoscopy and photographed after 
dilation of the pupils with one drop of 
tropicamid (5 mg/ml) and phenylephrine 
hydrochloride (100 mg/ml). 
The animals were sacrificed six days 
after the gene transfers, when the 
concentration of the transduced human 
VEGF-A protein is maximal in the 
vitreous humour (Kinnunen et al., 2006). 
 
 
Rat glioma model (IV) 
 
Rat glioma BT4C cells (a gift from Dr. 
Rolf Bjerkvig, Bergen, Norway) were 
obtained from fetal BDIX rats exposed to 
N-ethylnitrosourea (Sandmair et al., 
1999). Syngeneic BDIX male rats 
(Charles River Laboratories International, 
Inc., Wilmington, MA, USA) were injected 
with 104 BT4C cells resuspended in 10 µl 
of Optimem (GIBCO-BRL, Gaithersburg, 
MD, USA) to a depth of 2.5 mm into the 
right corpus callosum (Sandmair et al., 
1999). The rats were divided into two 
cohorts: group I, which received Adh15-
LO-1 gene therapy (n=12) and group II, 
which was a control group (n=5) and did 
not receive any treatment. Tumor growth 
was verified 14 days after cell injection by 
magnetic resonance imaging (MRI). On 
the next day, the animals received 
Adh15-LO-1 (2.7 x 1010 plaque forming 
units/ml) injection to a depth of 1.5, 2.0 
and 2.5 mm (2.5 µl per site), followed by 
two additional injections applied on the 
following day (at 2 mm depth at an angle, 
anteriorly and posteriorly, made by flexing 
the C-arm of the microinjection unit). 
Tumor growth was assessed by MRI 
again two and four weeks after the 
treatment. 
Those animals that did not exhibit any 
signs of a tumor on the first MRI, as well 
as those that had shown an extra-cranial 
tumor growth, were excluded from the 
study. The rest of the animals were used 
in the survival studies. Animals were 
sacrificed upon human endpoints. 
Survival was calculated in days from the 
day of BT4C cell inoculation.
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TISSUE PROCESSING (II-IV) 
 
Rabbit muscle samples (II) 
 
Rabbits were perfusion fixed with 1 % 
paraformaldehyde (PFA) in 0.05 M citrate 
buffer (pH 3.5). Muscle tissue samples 
were immersion fixed in 4 % PFA/7.5 % 
sucrose (pH 7.4) for 4 h, rinsed in 15 % 
sucrose (pH 7.4), embedded in paraffin 
and cut into paraffin sections (Rissanen 
et al., 2003a). Another set of animals was 
used to obtain snap frozen, fresh muscle 
tissue samples for RNA, protein, and 
enzyme activity analyses. In addition, 
muscle samples were snap frozen in 
isopenthane and processed into frozen 
sections. 
 
 
Rabbit eye samples (II) 
 
Vitreous samples collected from each 
animal were snap frozen in liquid nitrogen 
and stored at -70 °C until analyzed. One 
set of animals was perfusion fixed with 1 
% PFA in 0.05 M citrate buffer (pH 3.5) 
(Rissanen et al., 2003a). The eyes were 
enucleated and cut in half. The half 
containing the optic nerve was immersion 
fixed in 4 % PFA/7.5 % sucrose (pH 7.4) 
for 4 h, rinsed in 15 % sucrose (pH 7.4) 
overnight and embedded in paraffin 
(Kinnunen et al., 2006). 
Another set of animals was sacrificed 
without perfusion fixation. The eyes were 
enucleated and cut in half from the side 
of the optic nerve. The half containing the 
optic nerve was embedded in 33 % 
optimal cutting temperature (OCT) 
compound and processed for frozen 
sections. The other half was cut into 
longitudinal segments, which contained 
parts from the back of the eye all the way 
to the cornea, i.e. parts of the outer layer 
(sclera and cornea), the middle layer 
(choroid, ciliary body and the iris) and the 
innermost layer (the retina). The 
segments were snap frozen in liquid 
nitrogen and stored at -70 °C for RNA 
analysis. 
A third set of animals was sacrificed 
without perfusion fixation, the superior 
part of the eyes was identified for 
orientation, the eyes were enucleated, 
and the retinal whole-mounts were 
detached from the sclera and were post-
fixed for 24 h in the same fixative 
solution. 
 
 
Mouse tissue samples (II) 
 
Mice were perfused with phosphate 
buffered saline (PBS). Tissue samples 
were fixed for 1 h in 4 % PFA/PBS and 
immersed in PBS until being processed 
into paraffin sections. Fresh tissue 
samples were snap frozen in liquid 
nitrogen and stored at -70 °C until 
processed for nucleic acid isolations, lipid 
peroxidation analysis and caspase-3 
activity measurements. 
 
 
NUCLEIC ACID ISOLATIONS (I-
IV) 
 
mRNA (I, IV) was isolated from 
transduced cells using oligo(dT)-cellulose 
(Ausubel et al., 1992). Total RNA (II-IV) 
and genomic DNA (IV) were isolated 
from adenovirally transduced cells and 
tissues using TRIZOL reagent according 
to the manufacturer’s instructions. 
 
 
NORTHERN BLOTTING (I, IV) 
 
mRNA samples were electrophoresed 
on 1 % agarose/formaldehyde gels and 
transferred to a nylon membrane. 
Random-primed 32P-cDNA probes were 
synthesized using [32P]dCTP and Prime-
a-Gene labelling system (Promega, 
Madison, WI, USA) according to the 
manufacturer’s instructions. Northern blot 
hybrdizations were performed as 
described (Sambrook et al., 1989). 
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POLYMERASE CHAIN 
REACTIONS (PCR) (II-IV) 
 
Distribution of the transduced 15-LO-1 
was detected with polymerase chain 
reaction (PCR) from genomic DNA 
samples (IV). mRNA expression of the 
adenovirally transduced genes (II-IV) and 
endogenous rabbit α-actin (II-III) was 
detected with reverse transcription PCR 
(RT-PCR) from the total RNA samples 
after DNAse treatment and cDNA 
synthesis (Jalkanen et al., 2003). Each 
PCR mixture contained DNA or cDNA 
template, 1 U of DyNAzymeTM EXT DNA 
Polymerase (Finnzymes, Espoo, 
Finland), 20 pmol of each primer, 200 µM 
of each nucleotide (Fermentas Life 
Sciences, Burlington, Ontario, Canada), 
and 1.5 mM MgCl2 (3.5 mM for rabbit α-
actin) in 1 x PCR buffer (Fermentas Life 
Sciences, Burlington, Ontario, Canada) in 
a total volume of 50 µl. 
The primers for human 15-LO-1 were 
specific for the transduced gene, since 
the 5’ primer binds to the CMV promoter 
area of the adenovirus vector 5’ to the 
splice signals and the 3’ primer binds to 
the cloning junction of 15-LO-1. These 
primers result in the amplification of a 
956 bp fragment from the unspliced 
Adh15-LO-1 vector and a 129 bp 
fragment from the spliced messenger 
RNA produced from the recombinant 
Adh15-LO-1 virus. All the primers and 
PCR reaction conditions of the end-point 
PCRs are summarized in Table V. 
Quantitative RT-PCR was used to 
quantify the mRNA expression of 
endogenous rabbit PPAR-γ and VEGFR-
2 (II-III). The sequence-specific 
oligonucleotide primers for rabbit PPAR-γ 
(GenBank accession number AY166781) 
and VEGFR-2 (GenBank accession 
number AB017155) were 5'- 
TGAGCCTTGACTTGAACGAC-3' and 5'-
TGAGGACCCCGTCTTTATTC-3', and 
5'- ATGTACCAGACCATGCTTGA-3' and 
5'-AGTCTCTGACATCGGAAGAA-3', 
respectively. Rabbit 18S rRNA (GenBank 
accession number X06778) was used as 
a reference gene (Hofstaetter et al., 
2004). The assays and data calculations 
were performed as described (Roy et al., 
2005). In addition, quantitative RT-PCR 
was used to study the endogenous 
expression of eNOS and VEGFR-2 
mRNA in HUVECs by using TaqMan® 
Gene Expression Assays for human 
eNOS (Hs00167166_m1, Applied 
Biosystems, Foster City, CA, USA) and 
human VEGFR-2 (Hs00176676_m1, 
Applied Biosystems, Foster City, CA, 
USA), and TaqMan® ribosomal RNA 
control reagents for human 18s rRNA 
(Part Number 4308329, Applied 
Biosystems, Foster City, CA, USA), 
which served as the control gene. 
 
 
PROTEIN ISOLATION, SDS-
PAGE AND WESTERN 
BLOTTING (I) 
 
Retrovirally transduced cells (I) were 
suspended in 10 % sucrose/PBS, 
homogenized on ice with a tissue 
homogenizer and the supernatant was 
isolated by ultracentrifugation. Sodium 
dodecylsulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) was 
performed using 10 % gels in 0.025 M 
Tris/0.19 M glycine buffer pH 8.3 
containing 0.1 % sodium dodecyl sulfate. 
Transfer to nitrocellulose membranes for 
Western blotting was performed at 4 °C 
for 2 h at 200 mA. 15-LO-1 protein was 
detected using polyclonal rabbit anti-
human recombinant 15-LO-1 antibody 
(1:500 dilution) (Sigal et al., 1990), 
horseradish peroxidase-conjugated 
secondary antibody (1:3000 dilution) and 
4-chloro-1-naphthol substrate.
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HYDROXY FATTY ACID 
ANALYSIS (I-IV) 
 
Transduced cells were broken either 
by mechanical shearing or by three 
freeze-thaw cycles. The broken cell 
suspensions were incubated at 37 °C for 
15 min with 50 µM LA. Specific 15-LO 
inhibitor PD146176 (Sendobry et al., 
1997; Bocan et al., 1998) (a generous gift 
from Dr. Joseph Cornicelli, Pfizer, Ann 
Arbor, MI, USA) was tested in some 
experiments at a concentration of 10 µM. 
The inhibitor was added 15 min before 
the LA incubation. After the LA 
incubation, 25 µg of butylated 
hydroxytoluene was added as an 
antioxidant and 25 µg of triheptadecanoin 
as an internal standard. Lipids were 
extracted, hydrogenated, saponified, 
esterified, and acetylated, and the 
functionality of the transduced 15-LO-1 
protein was confirmed by measuring 15-
LO-1 enzyme activity with gas 
chromatographic hydroxy fatty acid 
analysis (Nikkari et al., 1995). Protein 
concentrations were measured according 
to (Lowry et al., 1951) using bovine 
serum albumin as a standard. 
 
 
NUCLEAR EXTRACTION AND 
ELECTROPHORETIC MOBILITY 
SHITF ASSAY (I) 
 
Retrovirally transduced ECV304 cells 
(I) were activated with either TNF-α, 
phorbol 12-myristate 13-acetate (PMA), 
thapsigargin, or H2O2 for 2 h. Nuclear 
extracts were prepared using 10 % 
Nonidet P-40 solution (Sen et al., 1996b). 
Electrophoretic mobility shift assays were 
performed by incubating the nuclear 
extracts with poly(dI-dC) and 32-P 
labeled NF-κB consensus oligonucleotide 
probe for 30 min at room temperature 
(Roy et al., 1998). Proteins were 
separated by electophoresis in a native 6 
% polyacrylamide gel and detected by 
autoradiography. The specificity of the 
NF-κB band was demonstrated by 
treating the nuclear protein extract with 
an excess of cold competitor probe or a 
cold mutant probe for 15 min before 
incubation with a labeled consensus NF-
κB probe (Sen et al., 1996a). 
 
 
ADHESION MOLECULE 
EXPRESSION (I) 
 
Retrovirally transduced ECV304 cells 
(I) were activated with either PMA or 
TNF-α for 24 h and with or without pre-
treatment with α-lipoate for 48 h. The 
expression of VCAM-1 and ICAM-1 was 
analyzed by flow cytometry using 
monoclonal VCAM-1 antibody 
(Immunotech, Cedex, France) followed 
by fluorescein isothiocyanate (FITC) -
labeled goat anti-mouse IgG monoclonal 
antibody (Coulter, Miami, FL, USA), and 
FITC-labeled monoclonal ICAM-1 
antibody (Immunotech, Cedex, France), 
respectively (Roy et al., 1998). 
 
 
CELL-CELL ADHESION ASSAY 
(I) 
 
Jurkat T cells (ATCC TIB-152) were 
fluorescently labeled with 5 µM calcein 
acetoxymethyl ester (Molecular Probes, 
Eugene, OR, USA) for 30 min at 37 °C 
(Roy et al., 1998). Retrovirally transduced 
ECV304 cells were cultured in 96-well 
tissue culture plates and activated with 
100 nM PMA for 24 h. Labeled Jurkat T 
cells were co-cultured with the ECV304 
clones for 1 h at 37 °C. The adhesion of 
the labeled Jurkat T cells to the ECV304 
clones was analyzed by measuring the 
fluorescence intensity of each well (Roy 
et al., 1998). 
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IMMUNOHISTOCHEMISTRY (II-
IV) 
 
The primary antibodies used in 
immunohistochemistry are summarized 
in Table VI. The avidin-biotin-horseradish 
peroxidase system (Vector Laboratories, 
Burlingame, CA, USA) and 3’-5’-
diaminobenzidine (DAB) color substrate 
(Zymed Laboratories, South San 
Francisco, CA, USA) were the detection 
agents used in all immunostainings. 
 
 
Table VI. Primary antibodies used in the immunostainings. 
 
Antibody Source Publication 
Mouse monoclonal anti-human CD31, clone JC/70A 
(endothelial cell marker) 
DAKO, Glostrup, 
Denmark II,III 
Goat polyclonal anti-human 15-LO-1 
Santa Cruz 
Biotechnology, 
Santa Cruz, CA, 
USA 
II 
Mouse monoclonal anti-human VEGF 
Santa Cruz 
Biotechnology, 
Santa Cruz, CA, 
USA 
II, III 
Mouse monoclonal anti-human eNOS 
BD Biosciences, 
San Jose, CA, 
USA 
II 
Mouse monoclonal anti-nitrotyrosine, clone 1A6 Upstate, Lake Placid, NY, USA II 
Mouse monoclonal anti-human PPAR-γ 
R&DSystems, 
Minneapolis, MN, 
USA 
II 
Mouse monoclonal anti-fetal liver kinase 1 
(VEGFR2) 
Santa Cruz 
Biotechnology, 
Santa Cruz, CA, 
USA 
II 
FITC-conjugated anti-lectin (Lycopersicon 
esculentum, tomato) 
Sigma-Aldrich, St. 
Louis, MO, USA III 
Mouse monoclonal anti-glial fibrillary acidic Sigma-Aldrich, St. Louis, MO, USA III 
Rabbit polyclonal anti-human 15-LO antibody CheY Sigal et al., 1990 IV 
Rabbit polyclonal anti-human active caspase-3 
Promega, 
Madison, WI, 
USA 
IV 
 
 
 
 
55 
ASSESSMENT OF ANGIOGENIC 
EFFECTS (II-III) 
 
Capillary perfusion was measured 
from rabbit hind limbs with contrast 
enhanced ultrasound (CEU) after a bolus 
injection of a second generation contrast 
agent (2 x 108 bubbles/ml, mean 
diameter 2.5 µm, SonoVue, Bracco, Italy) 
via the ear vein (Rissanen et al., 2005). 
Vascular permeability was analyzed by a 
modified Miles assay, where Evans Blue 
dye (Sigma-Aldrich, St. Louis, MO, USA) 
(30 mg/kg) was injected intravenously 30 
min before sacrifice. Animals were 
perfusion fixed with 1 % PFA in 0.05 M 
citrate buffer (pH 3.5). Evans Blue dye 
bound to the plasma proteins in the 
muscle tissue was extracted by 
incubation in formamide for 24 h at 60 
°C. The amount of bound Evans Blue dye 
was quantified with a spectrophotometer 
at 610 nm and the permeability ratio was 
calculated as the ratio between 
transduced tissue and intact control 
tissue after normalization for the tissue 
weights (Rissanen et al., 2003a). 
Capillary mean area (µm2) and 
capillary density (capillaries/myocytes) 
were measured from CD31-
immunostained sections by AnalySIS 
software (Soft Imaging System) 
(Rissanen et al., 2003a). 
Four peripheral areas of medullary 
rays from each whole-mounted retina 
stained with FITC-conjugated lectin were 
digitally imaged with Olympus DP50 
(Olympus, Tokyo, Japan) camera system 
operating on an Olympus BX40 
transmitted microscope. Retinal blood 
vessel diameters were measured using 
Adobe Photoshop CS3 software (Adobe 
Systems Incorporated, San Jose, CA, 
USA). 
 
 
NOS ACTIVITY (II) 
 
NOS activity was measured as 
relative nicotinamide adenine 
dinucleotide phosphate (NADPH) 
diaphorase activity from rabbit muscle 
tissues homogenized in solubilization 
buffer (0.1 M Tris-HCl, pH 7.4 containing 
0.5 % (v/v) Triton X-100, 1 mM EDTA, 1 
mM phenylmethylsulfonyl fluoride and 
protease inhibitor cocktail (Complete, 
Roche, Basel, Switzerland)). The 
homogenate supernatants were 
incubated with NADPH diaphorase 
medium (20 mg/ml β-NADPH, 0.5 mg/ml 
nitroblue tetrazolium and 0.5 % (v/v) 
Triton X-100 in 0.1 M Tris-HCl buffer, pH 
7.4) at 37 °C for 30 min. Incubations 
were also performed in the absence of β-
NADPH (blank) (Baum et al., 2002). 
Absorbance of the produced formazan 
was measured at 560 nm. The protein 
concentrations were measured by BCA 
Protein Assay Kit (Pierce, Rockford, IL, 
USA). The results were calculated as 
relative NADPH activity (∆E/mg 
protein/30 min) by subtracting the 
absorbance values obtained from the 
blank reactions from the absorbances 
obtained from the reactions containing β-
NADPH (Baum et al., 2002). 
 
 
ELISA (II-III and unpublished) 
 
Muscle tissues were homogenized in 
T-PER Tissue Protein Extraction 
Reagent (Pierce, Rockford, IL, USA) and 
the total protein concentrations of the 
tissue homogenates were measured with 
the BCA Protein Assay Kit (Pierce, 
Rockford, IL, USA). The protein 
expression of the transduced VEGF-A165 
(II-III), PlGF-2 (II) and VEGF-D∆N∆C 
(unpublished) was quantified from 
transduced muscle tissues by enzyme 
linked immunosorbent assays (ELISA) 
(Quantikine human VEGF, Quantikine 
mouse PlGF-2 and Quantikine VEGF-D, 
R&D Systems, Minneapolis, MN, USA). 
ELISAs were also performed from 
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HUVEC cell culture media and vitreous 
samples. 
 
 
LIPID PEROXIDATION ASSAY 
(IV) 
 
Lipid peroxidation, an indicator of 
oxidative stress, was measured from 
snap frozen liver samples according to 
the colorimetric BIOXYTECH® LPO-
586 lipid peroxidation assay (Oxis 
International, Inc., Portland, OR, USA). 
The assay is based on the reaction of a 
chromogenic agent, N-methyl-2-
phenylindole, with malondialdehyde 
(MDA) and 4-hydroxyalkenals, which are 
decomposition products of the unstable 
lipid peroxides. For the assay, the snap 
frozen tissue samples were homogenized 
in ice-cold 20 mM Tris buffer, pH 7.4, 
containing 5 mM butylated 
hydroxytoluene to prevent sample 
oxidation. The homogenates were 
centrifuged at 4 °C 3000 g for 10 min to 
remove large particles. The supernatants 
were used for the lipid peroxidation assay 
and for protein determination by 
Coomassie Plus Protein Assay Reagent 
Kit (Pierce, Rockford, IL, USA). 
 
 
DETECTION OF APOPTOSIS 
(IV) 
 
Apoptosis was detected from mouse 
liver paraffin sections using polyclonal 
antibody against the active form of 
caspase-3 (Table VI). Enzymatic 
caspase-3 activity in mouse liver samples 
was detected fluorometrically from tissue 
homogenates by measuring the 
proteolytic cleavage of the fluorogenic 
substrate Ac-DEVD-AMC (Calbiochem, 
La Jolla, CA, USA) at excitation 380 nm 
and emission 465 nm (Pulkkanen et al., 
2000). Protein concentrations of the 
tissue homogenates were determined 
with the Coomassie Plus Protein Assay 
Reagent Kit (Pierce, Rockford, IL, USA). 
MAGNETIC RESONANCE 
IMAGING (IV) 
 
MRI was used for tumor visualization. 
The rats were anesthetized with 
isoflurane (induction 5 % and 
maintenance 1.5 % with carrier gas of O2 
30 % and N2O 70 %) and fixed to a 
stereotactic holder. MRI data were 
acquired using a horizontal 4.7 T magnet 
(Magnex Scientific Ltd, Abington, UK) 
interfaced to a Varian (Palo Alto, CA, 
USA) UnityINOVA console and using an 
actively decoupled volume transmission 
coil and a quadrature surface receiver 
coil (Rapid Biomedical, Rimpar, 
Germany). T2-weighted images were 
measured using a spin echo sequence 
(echo time (TE) = 40 ms, repetition time 
(TR) = 2 s). A total of 17 slices, each of 1 
mm thickness, were imaged. The matrix 
size was 256x128 zero-filled to 256x256, 
with field of view (FOV) 40 mm2 yielding 
an in-plane resolution of 156 µm. 
Total tumor volume was processed 
and analysed using Matlab version 7.04 
(The MathWorks, Inc., Natick, MA, USA). 
Tumor volumes were calculated by 
delineating the tumor area in all the 
image slices, using premade macros. To 
minimize human errors, tumor volumes 
were measured independently by two 
individuals with the mean values of the 
two measurements being used. A 
multiplication factor to convert to tumor 
volumes, thus obtained in pixels into 
mm3, was calculated using the following 
formula; FOV in mm divided by the pixel 
size and squared. Multiplication factor 
was 0.0244. 
 
 
STATISTICS (II-IV) 
 
Results are presented as mean ± SD. 
All data were analysed by GraphPad 
Prism Software package. Statistical 
significance was evaluated using One-
Way ANOVA, followed by Newman-Keuls 
Multiple Comparison test, or Kruskal-
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Wallis test or Mann-Whitney test. 
Survival analysis was done using Kaplan-
Meier log rank test and tumor volume 
comparison was done with unpaired T-
test. A value of P < 0.05 was considered 
statistically significant.
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RESULTS 
 
CHARACTERIZATION OF THE 
RECOMBINANT RETRO- AND 
ADENOVIRUSES CONTAINING 
HUMAN 15-LO-1 cDNA (Original 
publications I-IV) 
 
Functionality of the recombinant retro- 
and adenoviruses containing human 15-
LO-1 cDNA was confirmed at the mRNA, 
protein and enzyme activity levels. 
Northern blot analysis of the retrovirus-
derived clones from both the packaging 
cell line PA317 and from ECV304 cells 
showed that the clones produced a full-
length transcript from the proviral DNA 
between the LTRs (I). Adenovirus 
mediated gene transfer of 15-LO-1 led to 
detection of a specific PCR fragment 
from 15-LO-1 mRNA with all three in vivo 
gene transfer techniques that were 
applied: in rabbit hind limb skeletal 
muscle after local intramuscular gene 
transfer (II), in rabbit eye tissue after 
intravitreal gene transfer (III), and in 
several organs after tail vein gene 
transfer in mice (IV). 
15-LO-1 protein expression was 
detected as an approximately 75 kDa 
protein from the retroviral 15-LO-1 clones 
by Western blotting, whereas no 
expression was detected from the control 
cells (I). Expression of 15-LO-1 after 
adenovirus mediated gene transfer was 
confirmed by immunohistochemistry from 
rabbit skeletal muscles, where 15-LO-1 
protein expression was localized in the 
capillaries (II). After tail vein gene transfer 
in mice, the transgene expression was 
predominant in liver where there was 
uniform expression. In spleen, 15-LO-1 
expression was localized to the interface 
between the white pulp and the red pulp 
(IV). 
Enzymatic activity of 15-LO-1 was 
confirmed from retroviral PA317 and 
ECV304 cell clones (I) and from 
adenovirally transduced RAASMC (II), 
ECV304 cells (III) and RAW264.7 mouse 
macrophages (IV) by a gas 
chromatographic method measuring 
hydroxy fatty acids (Nikkari et al., 1995). 
Incubation of the cells with LA led to 
specific induction in the production of the 
15-LO-1 metabolite 13-HODE. The 
proportion of 13-HODE of all the HODEs 
detected was 77 % on average. Induction 
of 13-HODE production was prevented 
by the specific 15-LO inhibitor PD146176 
(Figure 6). 
 
 
INDUCTION OF ADHESION 
MOLECULE EXPRESSION AND 
T CELL ADHESION (Original 
publication I) 
 
The activation of NF-κB, a 
transcription factor sensing various 
inflammatory stimuli and oxidative stress, 
was potentiated in the 15-LO-1 
expressing ECV304 cell clone in 
response to several stimuli, including 
PMA and TNF-α. The constitutive 
expressions of the adhesion molecules 
ICAM-1 and VCAM-1 were similar in 
retroviral clones expressing either E. coli 
β-galactosidase or human 15-LO-1. 
However, the expression in 15-LO-1 
clone was inducible by PMA and TNF-α 
via an NF-κB mediated mechanism, and 
the induction of ICAM-1 was shown to be 
inhibited by the antioxidant α-lipoate. 
Stimulation of the 15-LO-1 expressing 
ECV304 cells with PMA also led to 
significantly increased adhesion of T cells 
(Figure 7).
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Figure 6. Gas chromatographic HODE analysis from the adenovirally transduced 
cells after incubation with LA. Results are presented as mean ng HODE/mg protein ±SD. **, 
p<0.01 Adh15-LO-1 vs. untransduced and vs. AdlacZ; ***, p<0.001 Adh15-LO-1 vs. untransduced 
and vs. AdlacZ; One-Way ANOVA followed by Newman-Keuls Multiple Comparison test. Combined 
from original publications II-IV.
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Figure 7. Increased adherence of 
Jurkat T cells to ECVLO cells in 
response to PMA stimulation. 
Retrovirally transduced ECV304 cells 
expressing either E. coli lacZ (ECVLZ) or 
human 15-LO-1 (ECVLO) were stimulated 
with 100 nM PMA for 24 h and then co-
cultured with fluorescently labelled Jurkat T 
cells for 1 h. The results are presented as 
percent increase in the number of adhered 
Jurkat T cells adhering to ECVLO and ECVLZ 
cells following PMA stimulation. Three 
separate experiments were done in triplicate. 
P<0.0001, unpaired t test. From original 
publication I. 
PREVENTION OF 
ANGIOGENESIS INDUCED BY 
VEGF FAMILY MEMBERS 
(Original publications II and III) 
 
 
In articles II and III, the angiogenic 
findings previously reported for 
intramuscular VEGF-A165 gene transfer in 
rabbit hind limb skeletal muscles 
(Rissanen et al., 2003b), and in rabbit 
eyes after intravitreal gene transfer 
(Kinnunen et al., 2006) were confirmed. 
In addition, there were new findings that 
15-LO-1 almost completely abolished all 
of the angiogenic effects induced by 
VEGF
 
family members in the skeletal 
muscles and by VEGF-A165 in rabbit 
eyes. Capillary perfusion was significantly 
induced by VEGF-A165 in the skeletal 
muscles and PlGF-2 was even more 
potent than VEGF-A165 in this regard. 15-
LO-1 almost completely prevented the 
growth factor induced increases in 
perfusion (Figure 8).
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Figure 8. Adh15-LO-1 prevents AdhVEGF-A165 and AdmPlGF-2 induced increases in 
capillary perfusion. (A) CEU perfusion images were taken six days after gene transfer from 
semimembranosus muscles transduced with AdlacZ, Adh15-LO-1, Adh15-LO-1 + AdhVEGF-A165, 
AdhVEGF-A165, Adh15-LO-1 + AdmPlGF-2, and AdmPlGF-2 (see Table IV). Quantitative analysis of 
perfusion by CEU perfusion index between the transduced and intact semimembranosus muscles 
shows that AdhVEGF-A165 (B) and AdmPlGF-2 (C) significantly induce the CEU perfusion index and 
Adh15-LO-1 prevents this induction. n = 4 for Adh15-LO-1 + AdmPlGF-2 and AdmPlGF-2, and n = 8 
for all other groups. The results are presented as mean ±SD. ***, p<0.001 AdhVEGF-A165 and 
AdmPlGF-2 vs. all other groups, One-Way ANOVA followed by Newman-Keuls Multiple Comparison 
test. From original publication II. 
 
 
 Capillary size and number were 
significantly increased by VEGF-A165 both 
in the rabbit skeletal muscle and in the 
papilla of the rabbit eyes and 15-LO-1 very 
efficiently prevented these increases 
(Figure 9). In the retina, a significant 
increase in the capillary size was detected 
after VEGF-A165 gene transfer, whereas in 
the anterior parts of the eyes VEGF-A165 
increased the number of the capillaries. 
15-LO-1 prevented all these effects 
(original publications II and III). Capillary 
enlargement was also detected in muscles 
transduced with AdhVEGF-D∆N∆C, and 
the increase in capillary sixe was 
prevented by 15-LO-1 (unpublished 
results).
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Figure 9. 15-LO-1 prevents VEGF-A165 induced increases in the size and number of 
the capillaries in rabbit skeletal muscle and papilla. (A-D) CD31 immunohistochemistry 
from semimembranosus muscles transduced with AdlacZ (A), Adh15-LO-1 (B), Adh15-LO-1 + 
AdhVEGF-A165 (C), and AdhVEGF-A165 (D). Magnification 200x, scale bar 50 µm. (E-H) CD31 
immunohistochemistry from papilla after adenoviral intravitreal transductions with AdCMV (E), 
Adh15-LO-1 + AdCMV (F), Adh15-LO-1 + AdhVEGF-A165 (G), and AdhVEGF-A165 + AdCMV (H). 
Magnification 100x, scale bar 100 µm. Quantitative analysis of the capillaries shows that Adh15-LO-
1 blocked the AdhVEGF-A165 induced increase in the mean capillary area (µm2) in skeletal muscle 
(I) and in papilla (K) (***, p<0.001 AdhVEGF-A165 vs. all other groups). Adh15-LO-1 also prevented 
the induction in the capillary number by AdhVEGF-A165 in skeletal muscle (J) (**, p<0.01 AdhVEGF-
A165 vs. AdlacZ, ***, p<0.001 AdhVEGF-A165 vs. Adh15-LO-1, *, p<0.05 AdhVEGF-A165 vs. Adh15-
LO-1 + AdhVEGF-A165) and in papilla (***, p<0.001 AdhVEGF-A165 vs. all other groups). n = 12-
15/group for the muscles and n = 4-6/group for the eyes. Results are presented as mean ±SD. One-
Way ANOVA followed by Newman-Keuls Multiple Comparison test. From original publications II and 
III.
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 VEGF-A 165 resulted in a significant 52-
fold increase in capillary permeability in 
the rabbit skeletal muscles and 15-LO-1 
prevented this induction (II). VEGF-A165 
could mediate the angiogenic effects via 
˙NO, since it induced a significant 1.5-fold 
induction in NOS activity in the skeletal 
muscles. The amount of nitrotyrosine 
positive cells was significantly increased, 
as was also eNOS protein expression, 
whereas 15-LO-1 prevented all these 
effects (II). In addition, both VEGF-A165 
and PlGF-2 gene transfers induced the 
mRNA and protein expression of PPAR-γ 
and VEGFR-2 (II) (Figure 10), which may 
be evidence of a potentiation of the 
angiogenic signalling mediated by 
VEGFR-2. Induction of PPAR-γ and 
VEGFR-2 mRNA expression were also 
discovered in the eye tissue after 
intravitreal VEGF-A165 gene transfer (III), 
but these increases were not statistically 
significant.
 
 
Figure 10. Adh15-LO-1 prevents the AdhVEGF-A165 and AdmPlGF-2 induced 
expression of PPAR-γ and VEGFR2. (A and B) Quantitative RT-PCR analysis of endogenous 
rabbit PPAR-γ mRNA expression from the transduced semimembranosus muscles. (A) ***, p<0.001 
AdhVEGF-A165 vs. all other groups, (B) ***, p<0.001 AdmPlGF-2 vs. all other groups. (C and D) 
Quantitative RT-PCR analysis of endogenous rabbit VEGFR2 mRNA expression from the transduced 
semimembranosus muscles. (C) ***, p<0.001 AdhVEGF-A165 vs. all other groups, (D) ***, p<0.001 
AdmPlGF-2 vs. all other groups. n = 3-5/group. Results are presented as mean ±SD. From original 
publication II.
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15-LO-1 reduced the expression of 
VEGF-A165, PlGF-2 and the short, mature 
form of VEGF-D (VEGF-D∆N∆C, 
unpublished results) already at the 
mRNA level (II, III), resulting in reduction 
in protein expression of these growth 
factors in rabbit skeletal muscles (II), in 
transduced HUVECs (II) and in vitreous 
humor (III) (Figure 11). 15-LO-1 also 
reduced endogenous angiogenesis 
induced by ischemia in rabbit skeletal 
muscles (II).
 
 
Figure 11. Adh15-LO-1 reduces the production of the transduced human VEGF-A165 
and mouse PlGF-2 protein. Human VEGF-A (A) and mouse PlGF-2 (B) protein production in the 
transduced semimembranosus muscles. Results are presented as mean ±SD, n = 4-5/group. (A) **, 
p<0.01 AdhVEGF-A165 vs. AdlacZ, *, p<0.05 AdhVEGF-A165 vs. Adh15-LO-1 and Adh15-LO-1 + 
AdhVEGF-A165; (B) *, p<0.05 AdmPlGF-2 vs. all other groups, One-Way ANOVA followed by 
Newman-Keuls Multiple Comparison test. From original publication II. (C) VEGF-A production in 
HUVEC cell culture media 72 h after transduction. Results are presented as average VEGF-A ng/ml 
± SEM, n = 6/group. ***, p<0.001 AdhVEGF-A165 vs. Adh15-LO-1 + AdhVEGF-A165, One-Way 
ANOVA followed by Newman-Keuls Multiple Comparison test. ND = not detectable. From original 
publication II online data supplement. (D) Concentration of human VEGF-A in the vitreous. Results 
are presented as mean ±SD, n = 16/group. p<0.001 AdhVEGF-A165 + AdCMV vs. AdCMV, p<0.001 
AdhVEGF-A165 + AdCMV vs. Adh15-LO-1 + AdCMV, p<0.01 AdhVEGF-A165 + AdCMV vs. Adh15-
LO-1 + AdhVEGF-A165. Kruskal-Wallis test followed by Dunn’s multiple comparison test. From 
original publication III. 
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INDUCTION OF LIPID 
PEROXIDATION AND 
APOPTOSIS (Original publication 
IV) 
 
Tail vein gene transfer of Adh15-LO-1 
led to highest expression of the transgene 
in mouse liver and spleen. 15-LO-1 
induced lipid peroxidation in mouse liver, 
detected as an increased production of 
lipid peroxidation end products MDA and 
4-hydroxynonenal (4-HNE) (Figure 12). 
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Figure 12. Lipid peroxidation analysis 
from the mouse livers. The results are 
presented as mean nmol MDA and 4-HNE/g 
protein ±SD. n = 8 for AdlacZ and n = 12-13 for 
Adh15-LO-1. ***, p<0.001; *, p<0.05, Mann-
Whitney test. From original publication IV. 
Induced lipid peroxidation was 
followed by induction of caspase-3 
mediated apoptosis (Figure 13). 
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Figure 13. Caspase-3 enzymatic 
activity from mouse livers. The results 
are presented as mean relative fluorescence 
units ±SD. n = 3-4 for AdlacZ and n = 7-8 for 
Adh15-LO-1. ***, p<0.001, Mann-Whitney 
test. From original publication IV. 
 
 
PROLONGED SURVIVAL IN RAT 
MALIGNANT GLIOMA MODEL 
(Original publication IV) 
 
 15-LO-1 and its reaction product 
13(S)-HODE have been shown to be pro-
apoptotic and anti-tumorigenic in various 
cell lines in vitro, in several animal 
models and also in vivo in some cancer 
types (Kuhn et al., 2002). However, since 
conflicting effects of 15-LO-1 in 
tumorigenesis have been reported in 
various models depending on the tissue 
and cancer type, the effect of 15-LO-1 on 
tumorigenesis in a rat malignant glioma 
model was tested in this study. A 
tendency towards reduced tumor volume 
was detected in the 15-LO-1 treated 
animals and in this model 15-LO-1 
significantly prolonged the survival of the 
animals (Figure 14). 
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Figure 14. Kaplan-Meier survival 
analysis of Adh15-LO-1 gene therapy. 
Rats after implantation of BT4C cells 
were treated with Adh15-LO-1 (n=12) or 
followed up as control animals (n=5). The 
median survival of the treated and control 
animals were 42.5 days and 36.0 days, 
respectively (p=0.001). From original 
publication IV.
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DISCUSSION 
 
CHARACTERIZATION OF THE 
RECOMBINANT RETRO- AND 
ADENOVIRUSES CONTAINING 
HUMAN 15-LO-1 cDNA (Original 
publications I-IV) 
 
Western blotting analysis of the 
PA317 clones confirmed that the 
recombinant 15-LO-1 retrovirus produced 
correct size of 15-LO-1 protein, 
approximately 75 kDa (I), in good 
agreement with previous reports (Sigal et 
al., 1990; Kühn et al., 1993b). 
After tail vein gene transfer in mice, 
the transgene expression was 
predominant in liver (IV), in accordance 
with previous experiments using soluble 
macrophage scavenger receptor A 
(Jalkanen et al., 2003) and with the 
general hepatotropism of adenovirus 
(Wood et al., 1999). In spleen, 15-LO-1 
expression localized to the interface 
between the white pulp and the red pulp 
(IV), as previously seen after 
intravascular gene delivery in rabbits and 
was possibly related with loose 
fenestrated endothelium in this region 
(Hiltunen et al., 2000). 
 
 
INDUCTION OF ADHESION 
MOLECULE EXPRESSION AND 
T CELL ADHESION (Original 
publication I) 
 
15-LO-1 induced NF-κB mediated 
expression of the adhesion molecules 
VCAM-1 and ICAM-1, as well as T cell 
adhesion on the 15-LO-1 expressing 
ECV304 cells. These results suggest that 
15-LO-1 may have pro-atherogenic 
properties in the early phases of 
atherosclerosis by inducing adhesion 
molecule expression and by mediating 
the adhesion of inflammatory cells to the 
endothelium. 
Several reports support our findings in 
revealing similar effects of 15-LO-1 on 
the expression of adhesion molecules 
and on the adhesion of inflammatory 
cells. Transient overexpression of 15-LO-
1 in aortic ECs increases TNF induced 
VCAM-1 expression (Wölle et al., 1996). 
ICAM-1 expression is also induced in 
aortic ECs by 15-LO-1 or 15-HPETE 
(Sordillo et al., 2008). Fibroblasts 
overexpressing 15-LO-1 generate 
bioactive, minimally oxidized LDL, which 
stimulates monocyte chemotaxis and 
adhesion to ECs (Sigari et al., 1997). 
Inhibition studies with short hairpin RNA 
to knock down the endogenous 12/15-LO 
expression in mouse macrophages and 
vascular SMCs leads to reduced oxidant 
stress, chemokine and adhesion 
molecule expression and cellular 
adhesion (Li et al., 2005). 
Production of 12/15-LO metabolites 
12(S)-HETE and 13(S)-HODE is induced 
in diabetic mice. Monocyte adhesion to 
ECs derived from these mice is induced, 
and the induction can be prevented by 
inhibiting 12/15-LO. The adhesion is 
mediated by the interactions of monocyte 
integrins with endothelial VCAM-1, 
connecting segment 1, fibronectin and 
ICAM-1 (Hatley et al., 2003). Increased 
monocyte adhesion is mediated by these 
same factors also in 12/15-LO transgenic 
mice, where ICAM-1 expression is 
induced several-fold (Reilly et al., 2004) 
via activation of NF-κB (Bolick et al., 
2005). 
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PREVENTION OF 
ANGIOGENESIS INDUCED BY 
VEGF FAMILY MEMBERS 
(Original publications II and III) 
 
 Previous studies from our research 
group have explored the angiogenic 
effects of different VEGF family members 
in rabbit hind limb skeletal muscles by 
adenovirus mediated gene transfers. The 
VEGF family members induce capillary 
perfusion and vascular permeability, and 
also increase both number and size of the 
capillaries (Rissanen et al., 2003b). Our 
group has also created a rabbit model, 
where intravitreal VEGF-A165 gene transfer 
induces neovascularization and increases 
vascular leakage in rabbit eye, resembling 
the pathological changes detected in 
diabetic retinopathy (Kinnunen et al., 
2006). In articles II and III, the angiogenic 
findings previously reported with 
intramuscular VEGF-A165 gene transfer in 
rabbit hind limb skeletal muscles, and in 
rabbit eyes after intravitreal gene transfer 
were confirmed. 
 The results also showed that VEGF-
A165 could mediate the angiogenic effects 
in the skeletal muscles partly by inducing 
NOS activity and eNOS protein 
expression. Endothelial ˙NO is required in 
arteriolar vasodilatation (Ignarro et al., 
1987), and stimulation of ˙NO release both 
endogenously and exogenously can 
increase capillary diameters (Bloch et al., 
1995). Previous studies by our group have 
shown that AdhVEGF-A165 gene transfer 
induces arteriogenesis, as nearly all 
enlarged capillaries in the AdhVEGF-A165 
transduced muscles have a pericyte 
coverage positive for α-smooth muscle 
actin (Rissanen et al., 2003b; Rissanen et 
al., 2005). Therefore, it is likely that the 
capillaries, which have been shifted 
towards an arteriolar phenotype, can 
undergo ˙NO mediated vasodilatation. In 
the combination gene transfer groups, the 
induction of vasodilatation was prevented 
by 15-LO-1. This can be partly mediated 
by the prevention of growth factor 
expression and the signalling cascade 
mediated by the growth factors, but also 
partially by catalytic consumption of ˙NO 
by 15-LO-1 (O'Donnell et al., 1999; Coffey 
et al., 2001) (Figure 15). 
In addition to inducing eNOS 
expression and NOS activity, VEGF-A165 
and PlGF-2 could also mediate the 
angiogenic effects by inducing the 
expression of PPAR-γ and VEGFR-2 (II-
III). 15-LO-1 product 13-HODE is an 
endogenous activator and ligand of 
PPAR-γ (Nagy et al., 1998). Interestingly, 
it has been shown in a rabbit eye model 
that PPAR-γ binding to the VEGFR-2 
promoter induces VEGFR-2 expression, 
but ligand binding to PPAR-γ actually 
results in an inhibition of VEGFR-2 
expression (Sassa et al., 2004). 
Based on our findings, we 
hypothesize that 15-LO-1 affects VEGF-
A165 induced neovascularization both in 
transduced cells and via its secreted 
products. Thus, 15-LO-1 expression in 
the cells next to the vascular ECs can 
directly inhibit VEGF-A165 expression and 
prevent angiogenic signal transduction 
events mediated by secreted VEGF-A165, 
whereas in 15-LO-1 transduced ECs 15-
LO-1 products binding to PPAR-γ prevent 
the VEGF-A165 induced expression of 
VEGFR-2 (Figure 15). PPAR-γ ligands 
have previously been shown to reduce 
VEGFR-2 expression and inhibit 
angiogenesis in vitro (Xin et al., 1999), as 
well as to inhibit choroidal (Murata et al., 
2000) and corneal neovascularization 
(Xin et al., 1999; Panigrahy et al., 2002; 
Sarayba et al., 2005) in vivo. 
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Figure 15. Proposed mechanism for 
the inhibitory effect on angiogenesis 
by 15-LO-1. VEGF mediated angiogenic 
signalling involves VEGF binding to VEGFR-2 
and increased ˙NO production resulting in 
angiogenesis and vasodilatation of the 
capillaries. We hypothesize that the 15-LO-1 
mediated prevention of growth factor 
expression blocks these signalling cascades 
by preventing VEGF induced increases in 
PPAR-γ and VEGFR-2 expression as well as 
increases in NOS activity. From original 
publication II. 
 
Very little is known about the effects 
of 15-LO-1 on angiogenesis. Transgenic 
mice overexpressing 15-LO-1 in the 
vascular wall under the preproendothelin-
1 promoter (Harats et al., 1995) have 
been used to test the effects of the 
vascular overexpression of 15-LO-1. In 
the Lewis lung carcinoma model, the lung 
metastases occurring in the 15-LO-1 
transgenic mice have an extensive 
hemorrhagic necrotic core, a higher 
number of apoptotic cells and also 
multiple small blood vessels arranged in 
a complicated network (Harats et al., 
2005). 
These studies showed that 15-LO-1 
could reduce the expression of the VEGF 
family growth factors already at the 
mRNA level, resulting in very low 
production of the growth factor proteins. 
15-LO-1 might affect the production of 
the transduced human VEGF-A165, 
mouse PlGF-2 and human VEGF-
D∆N∆C either by preventing their 
transcription or by destabilizing the 
transcripts, or both. VEGF-A165 mRNA 
production and stability are both highly 
regulated. VEGF-A165 transcription is 
induced in hypoxia by HIF-1α (Forsythe et 
al., 1996) and the mRNA is stabilized by 
several factors binding to the 3’ UTR 
(Levy et al., 1998; Shih et al., 1999; Liu et 
al., 2002). PlGF transcription is induced 
by BF-2 (Zhang et al., 2003) and also in 
hypoxia, by metal response element-
binding transcription factor 1 (Green et 
al., 2001). 
However, the constructs used in these 
studies lack all the regulatory elements of 
the endogenous human VEGF-A165, 
mouse PlGF-2 and human VEGF-
D∆N∆C, containing only the protein 
coding regions under CMV promoter. It is 
unlikely that the reduction in the mRNA 
expression of the transduced growth 
factors would be attributable to blocking 
of the CMV promoter, since the human 
15-LO-1 cDNA in our adenovirus 
construct is also under a CMV promoter, 
and there was no reduction in the 
expression of the transduced human 15-
LO-1 in the combination gene transfer 
groups. Thus, the most likely explanation 
is that 15-LO-1 expression leads to 
destabilization of the growth factor 
transcripts by an as yet unidentified 
mechanism that would affect the coding 
sequences of these growth factors. The 
independence of the 15-LO-1 effect on 
the constructs is further supported by our 
finding that 15-LO-1 also reduced 
endogenous angiogenesis induced by 
ischemia in rabbit skeletal muscles (II). 
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INDUCTION OF LIPID 
PEROXIDATION AND 
APOPTOSIS (Original publication 
IV) 
 
 15-LO-1 induced lipid peroxidation in 
mouse liver, detected as MDA and 4-HNE. 
The induced synthesis of the lipid 
peroxidation end products was followed by 
increased activity of caspase-3. These lipid 
peroxidation end products, especially 4-
HNE, have been shown to induce apoptosis 
in several different cell lines via caspase 
activation (Liu et al., 2000; Ji et al., 2001; 
Zhang et al., 2001; Choudhary et al., 2002; 
West et al., 2004; Ferrington et al., 2006; Li 
et al., 2006b). Our findings support the pro-
apoptotic role of 15-LO-1 and its reaction 
products, and indicate that the lipid 
peroxidation induces apoptotic process 
mediated by increased caspase-3 activity. 
Thus, 15-LO-1 could be a potential 
therapeutic molecular target for the 
modulation of apoptosis in human disease. 
PROLONGED SURVIVAL IN RAT 
MALIGNANT GLIOMA MODEL 
(Original publication IV) 
 
 15-LO-1 showed a tendency in reducing 
the tumor volume and significantly prolonged 
the survival of the animals in the rat 
malignant glioma model. In a previous study, 
PPAR-γ ligand has been shown to inhibit the 
growth of primary glioblastoma by 
suppressing angiogenesis via reduction in 
vessel density and EC proliferation, as well 
as by reduction of VEGF production by the 
tumor cells (Panigrahy et al., 2002). 
There are no previous reports about the 
outcomes of 15-LO-1 gene therapy in animal 
tumor models of malignant glioma. This 
study reveals that adenoviral 15-LO-1 gene 
transfer significantly prolonged the survival 
of the animals in BT4C rat malignant glioma 
model. These results highlight the 
importance of performing further studies to 
evaluate the potential of 15-LO-1 in the 
treatment of malignant glioma.
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SUMMARY AND 
CONCLUSIONS 
 
 
Studies included in this thesis provide 
new information about the role of 15-LO-
1 in the development of atherosclerosis, 
and in angiogenesis and tumorigenesis. 
Both retro- and adenovirus mediated 
gene transfer techniques were 
successfully applied to produce functional 
15-LO-1 protein in in vitro and in vivo 
gene transfer studies. 
These studies support the pro-
atherosclerotic role of 15-LO-1 in the 
early development of atherosclerosis by 
showing that 15-LO-1 potentiates the 
activation of the inflammation and redox 
sensitive transcription factor NF-κB, 
leading to induction in the expression of 
NF-κB regulated adhesion molecules and 
consequently, increased adhesion of 
inflammatory cells. 
Our findings show that 15-LO-1 very 
efficiently prevents the angiogenic effects 
mediated by VEGF family members in 
two different animal models, i.e. in rabbit 
hind limbs and eyes. In addition, reduced 
endogenous angiogenesis by 15-LO-1 
was shown in an ischemic rabbit hind 
limb model. Based on these results, 15-
LO-1 appears to have potential in the 
treatment of pathologic angiogenic 
conditions, for example in neovascular 
ocular diseases. 
In addition, the detected prolongation 
of survival by 15-LO-1 in rat malignant 
glioma model indicates that further 
studies are needed to evaluate the 
potential of 15-LO-1 in the treatment of 
malignant glioma.
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